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1. Introducing protein intrinsic disorder phenomenon  
 
Proteins are the major component of the living cell. They play crucial roles in the maintenance of life, 
and their dysfunctions are known to cause different pathologies. One of the best-understood 
function of proteins is catalysis (i.e. enzymatic activity), which attracted the major attention in the 
early days of protein science and led to the elaboration of the “lock and key” model by Fisher. 
Central to this model is the notion that the correct shape of the substrate can fit into the active site 
of the enzyme for enabling an efficient and specific catalysis, as observed for enzymes that hydrolyze 
β- but not α-glycosidic bonds.1 Throughout the 20th century, tens of thousands of structures have 
been solved and deposited in the Protein Data Bank (PDB), supporting again the necessity of a 3-D 
structure for functionality. The explanatory power of these 3-D structures continued to reinforce the 
static view of protein structure that remained unquestioned. In contrast to this view, already in 1958, 
Koshland suggested the “induced-fit” model based on the observations that some enzymes could act 
on differently shaped substrates and hence a degree of flexibility is inevitable in function.2 
 
Furthermore, questions such as “what does the missing electron density in most of the deposited 
structures in the PDB correspond to?”, “why some proteins are highly sensitive in vitro to 
proteolysis?”, and “why some proteins possess a particular behavior during the purification 
process?” further opened eyes towards flexibility  and focused  attention on proteins basically 
distinct from well-known globular proteins. A combined answer to these questions ruled out flexible 
proteins as artifacts and enlightened the “dark side” of Structural Biology, that of disordered proteins 
(i.e. proteins that lack 3-D structure). This review provides a detailed description of those proteins 
that broke the protein rules by their inherent flexibility and peculiar features, now generally termed 
“intrinsically disordered” proteins (IDPs) or regions (IDRs). This review is intended as a general 
introduction to the series of thematic reviews in this special issue of Chemical Reviews on IDPs. Our 
key message is that IDPs possess no well-defined 3-D structure but rather adopt an ensemble of 
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conformations in solution, yet they are functional. A literature survey is provided by summarizing the 
main aspects of IDPs that led to an exponential increase of interest in these proteins. Moreover, 
through the different parts of this review, biochemical and biophysical approaches that are 
frequently used to assess intrinsic disorder are detailed. 
 2. Historical overview: Role of bioinformatics in establishing the IDP field  
 
It is now half a century since the first crystal structure of a protein (e.g. the atomic structure of 
myoglobin determined in 1958 by John Kendrew3) was published leading to the “birth” of Structural 
Biology. Soon after, the field grew rapidly with a dozen of atomic structures of proteins being 
published by the early 1970’s, leading to the establishment of the predecessor of PDB, the 
Brookhaven Data Bank.4,5 A well-folded, albeit dynamic, structure was thought to be the hallmark of 
protein function. This view was also built on the success of the previous half a century of the lock-
and-key view explaining the specificity of enzymes (Fig. 1A) and complementarity of antibody to 
antigen structure. The classical structure-function paradigm is centered on the idea that protein 
function depends on a well-defined three-dimensional (3-D) structure.  
 
Indeed, enzymes have a rather well-defined binding pocket for the formation of an enzyme-substrate 
(ES) complex (Fig. 1A), which ensures a tight fit between the binding pocket and the substrate (Fig. 
1B). The fact that conditions causing denaturation of proteins (treatment by acid, alkali or urea) lead 
to the loss of enzyme activity lent strong support to the protein structure-function paradigm.  
Consequently, the notion that many proteins or regions of proteins could be not ordered, but 
intrinsically disordered was unacceptable for a long time. Indeed, computational studies carried out 
as early as in 2000 predict that ordered proteins and domains cover only about half of the sequence 
space in various proteomes,6 which has led to “breaking the protein rules”.7 
 
The re-adaptation of the structure-function paradigm started as early as 1998 when Romero et al. 
predicted that more than 15,000 proteins in the Swiss Protein (SwissProt) database contain 
intrinsically disordered regions (IDRs) of at least 40 consecutive amino acids.8 Soon after, Wright and 
Dyson unveiled in 1999 that a large proportion of gene sequences are likely to be unfolded in 
solution, under native, functional conditions.9  
 
Through the last years, the terminology seem to have settled on “intrinsically disordered”,10 for 
proteins/regions that exist as dynamic ensembles, within which atom positions and backbone 
Ramachandran angles exhibit extreme temporal fluctuations without specific equilibrium values.8,11-16 
Their detailed characterization suggests that our traditional views of protein structure and function 
need to be re-assessed. 
3. Computational means for IDPs analysis 
 
3.1. Sequence peculiarities of IDPs    
  
The frequency of amino acids in disordered proteins significantly differs from that of ordered 
proteins.11,12,16 Amino acids frequencies plotted as a function of the flexibility index of residues show 
a distinctive pattern17 (Fig. 2): IDPs are often enriched in charged and structure-breaking residues 
(Pro and Gly) and in Ala. This collection of amino acids has been called “disorder promoting amino 
acids”. On the other hand, these proteins are depleted in hydrophobic and aromatic residues and 
also possess fewer Cys and Asn residues, collectively termed “order promoting amino acids”.18,19 It is 
generally thought that the absence of structure is encoded by the amino acid sequence. The ensuing 
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low mean hydrophobicity and a high net charge represents an important prerequisite for the 
absence of a compact structure in proteins under physiological conditions,15 because it provides less 
driving force for protein compaction while also contributing to charge-charge repulsion. This simple 
principle can be applied to predict IDPs by plotting the absolute net charge as a function of the mean 
normalized hydrophobicity, a plot denoted as charge-hydropathy (CH) plot or Uversky plot (Fig. 3).15 
In this plot, IDPs cluster in the high net charge - low net hydrophobicity half of the plane (Fig. 3), and 
the distance from the separating line (the formula of the linear function is: <R>=2.743<H>-1.109) 
may carry information on the extent and type of disorder for the whole chain (Fig. 3).20,21 
 
Protein disorder is also related to low sequence complexity (i.e. repetitiveness and limited diversity 
in amino acid composition).22,23 Accordingly, protein disorder abounds in certain types of charged 
and Pro-rich repetitive regions.24 25% of all amino acids in the SwissProt database are found in such 
regions, and 34% of all proteins have at least one such segment.11 It is to be noted though that some 
special cases of low-complexity sequences are found in proteins with a certain amino acid 
periodicity, yet ordered such as coiled-coils (collagen, for example). This biased composition together 
with these peculiar sequence features enabled the development of reliable computational tools for 
the analysis of structural disorder. 
 
3.2. Computational tools for disorder prediction 
 
The recognition of disordered regions from sequence facilitates the functional annotation of proteins 
and is instrumental in delineating protein domains amenable to crystallization.25,26 To this end, many 
disorder predictors have been developed.25-27 (cf. also the table in the Wikipedia article found at 
http://en.wikipedia.org/wiki/Intrinsically_unstructured_proteins).The reliability of disorder 
prediction benefits from the use of several methods based on different concepts, different 
physicochemical parameters, or different implementations.25-29 In principle, this problem can be 
approached from three distinct directions:  
 
1) Simple amino acid propensities reflecting some basic physical or sequence features. Such 
propensity-based predictors rely on simple statistics of amino acid propensity, the physical/chemical 
features of amino acids or on a preliminary concept on the physical background of disorder. The CH-
plot 15 with its derivative FoldIndex,30 PreLink,31 and GlobPlot,32 to name few, fit into this category.  
 
2) Machine-learning algorithms (MLAs) are trained on datasets of disordered regions. Presently three 
databases of experimentally characterized disordered proteins are available: the Database of Protein 
Disorder, DisProt (http://www.disprot.org/),33 IDEAL (http://www.ideal.force.cs.is.nagoya-
u.ac.jp/IDEAL/),34 and MobiDB (http://mobidb.bio.unipd.it/),35 with the former being the largest 
publicly available database, with about 1500 different regions. PONDR,23 DisEMBL,36 DISOPRED2,37 
and RONN,38 to name few, fall in this category of predictors since they have been trained on disorder 
data coming from either short regions of missing density from the PDB or from nuclear magnetic 
resonance (NMR) or from the DisProt database.33 Regions of missing electron density in the PDB are 
generally short, as long regions prevent crystallization.25 As such, short disorder is over-represented 
in the database of disordered regions, and hence these predictors tend to perform better in 
predicting short disorder than long disorder.  
 
3) The tendency of amino acids to make or avoid contacts with each other. The underlying idea is 
that IDPs are unfolded because they cannot make sufficient inter-residue contacts to overcome the 
large decrease in configurational entropy during folding. A simple statistical analysis of residue 
contact numbers is performed by FoldUnfold39 that calculates the expected average number of 
contacts per residue from the amino acid sequence alone. IUPred40,41 evaluates the energy resulting 
from inter-residues interactions, based on their inter-residues contacts in globular proteins.25,42 Since 
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these predictors are not trained on data sets of disordered regions they avoid the shortcomings and 
biases associated with these disordered datasets. Therefore, they are expected to perform better 
than the former methods on disordered proteins presently under-represented in training datasets 
(i.e., fully or mostly disordered proteins). 
 
Another non-automated method that is very useful for unveiling unstructured regions is hydrophobic 
clusters analysis (HCA).43 HCA provides a two-dimensional helical representation of protein 
sequences in which hydrophobic clusters are plotted along the sequence.43 As such, HCA is not stricto 
sensu a predictor, nevertheless, disordered regions are recognizable as they are depleted (or even 
devoid) in hydrophobic clusters (an HCA plot is presented in Fig. 4). The power of HCA analysis relies 
also on its ability to highlight coiled-coils, regions with a biased composition and regions with 
potential for induced folding (i.e. a disorder-to-order transition upon binding to a partner or ligand) 
(see also section 6.3).  
 
Predictors can also be classified based on the binary nature of the prediction. Examples of binary 
predictors are the CH-plot and the cumulative distribution function (CDF) analysis.20,44 The CDF 
analysis summarizes the per-residue predictions by plotting predicted disorder scores against their 
cumulative frequency, which allows ordered and disordered proteins to be distinguished based on 
the distribution of prediction scores.20,44 
 
The CH-CDF plot (see Fig. 5) is an analytical tool combining the outputs of two binary predictors, the 
CH-plot and the CDF plot.45,46 The vertical distance on the CH-plot from the location of the protein to 
the boundary line is a scale of disorder (or structure) tendency of the protein (Fig. 5A). This distance 
is referred to as the CH-distance. In CDF-plots, curves of ordered proteins tend to stay on the upper 
left half, whereas curves of disordered proteins tend to locate at the lower right half of the plot. An 
approximately diagonal boundary line separating the two groups can be identified and the average 
distance of the CDF curves from this boundary (CDF-distance) is a measure of the disorder (order) 
status of a given protein (Fig. 5B). The CH-CDF plot is based on both the CH-distance and the CDF-
distance (Fig. 5C).45,46 It provides very useful information on the general disorder status of a given 
protein. After setting up boundaries at CH=0 and CDF=0, the entire CH-CDF plot can be split into four 
quadrants. Starting from the upper right quadrant, by taking the clockwise sequence, the four 
quadrants are named Q1 (upper right), Q2 (lower right), Q3 (lower left), and Q4 (upper left). Proteins 
in Q1 are structured by CDF, but disordered by CH; proteins in Q2 are predicted to be structured by 
both CDF and CH; proteins in Q3 are disordered by CDF but structured by CH; and proteins in Q4 are 
predicted to be disordered by both methods. The location of a given protein in this CH-CDF plot gives 
information about its overall physical and structural characteristics. Fig. 5D shows the application of 
this tool for the analysis of ribosomal proteins.  
 
In general, low sequence complexity, low predicted secondary structure content and high sequence 
variability constitute an indicator of flexibility of proteins or protein domains.26 It should be stressed 
that it is difficult and maybe impractical to establish the “best” predictor at the moment. Some 
predictors perform better on short disordered regions (i.e. DISOPRED2 and PreLink) while other 
predictors (IUPred for instance) perform well in predicting long disordered segments and finally 
some predictors, such as PONDR, GlobPlot and FoldIndex, have been trained on both short and long 
disorder and provide a balanced performance.25 Therefore, to avoid pitfalls, different predictors 
should be combined, as performed by metapredictors that seek a consensus of the scores of 
different predictors relying on different principles (PONDR-FIT for instance).47 Alternatively, one 
could simply use publicly available servers allowing multiple predictions, such as “MeDor” 
(MEtaserver of DisORder), a server that does not provide a consensus prediction but is intended to 
speed up the analysis of protein disorder thanks to the simultaneous submission and retrieval of 
various disorder predictions, the prediction of secondary structures and a HCA plot (see Fig. 4).48 (For 
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a general procedure to predict structural disorder, see ref.25 ; for a detailed description of 
metapredictors, see ref.27)  
 
An extreme extension of the combined use of different predictors is the combination of in silico and 
experimental approaches with the ultimate goal of inferring as many structural information as 
possible while limiting the experimental characterization to relatively low-demanding experiments. 
An illustration of such an approach can be found in ref.49 where a spectroscopic and computational 
analysis were combined. In that study, the authors plotted the ratio between the Θ222 and Θ200 
(Θ222/Θ200) of a set of IDPs under study, along with the Θ222/Θ200 ratio of a set of well-characterized 
random coil-like and premolten globule-like proteins.13 The authors then set an arbitrary threshold of 
the Θ222/Θ200 ratio that allows discrimination between random coil-like IDPs and IDPs adopting a 
premolten-like conformation. Then, they generated a plot in which the distance of each IDP under 
study from this threshold was plotted as a function of its CH-distance in the CH plot. This analysis was 
intended to combine, and hence extend, two previous methods13,15 so as to allow random coil-like 
forms to be readily and easily distinguished from premolten globule-like forms among proteins 
predicted to be intrinsically disordered by the hydropathy/charge method. In the resulting plot, 
increasingly negative CH distances designate proteins with increasing disorder, while increasingly 
positive Θ222/Θ200 distances designate IDPs becoming progressively more collapsed, as a 
consequence of an increased content in regular secondary structure. Thus, the left bottom quadrant 
is expected to correspond to IDPs adopting a random coil-like conformation, while the right bottom 
quadrant is supposed to designate IDPs adopting a premolten globule-like conformation. 
 
Although the number of known disordered sequences based on the analysis of amino acid sequence 
parts missing in the crystal structure of proteins and analysis of properties of already characterized 
IDPs and their sequences is not too large, it is not too small either. In fact, the available data are 
sufficient to create reliable computational tools (i.e., the existing data are enough to generate both 
training and testing sets needed for the development of predictors). These tools are able to rather 
accurately find sequence features similar to those used in training. The progressively increasing 
number of disorder predictors is an obvious reflection of these facts. The situation is further 
complicated by the fact that the structural spectrum of intrinsic disorder is very broad (in fact, it is 
much broader than that of ordered proteins). This means that existing computational tools and their 
various combinations are doomed to be sensitive to some specific (and rather limited) features and 
would not be able to cover the whole spectrum of disorder. We consider the realm of computational 
tools for disorder prediction to be similar to the multiparametric experimental approach for 
structural characterization of proteins. In that approach, although each technique is able to see only 
a part of picture, the whole picture still can be restored by looking to the structure at different angles 
(i.e., using different techniques sensitive to the different levels of protein structure). Obviously, it 
would be more appropriate to say that the generalized criteria for disorder are still evolving and that 
only the availability of a reasonably large number of experimentally characterized IDPs will provide a 
solid basis for justified protein disorder prediction. On the other hand, this does not mean that these 
predictors should not be developed before such large number of experimentally characterized IDPs 
will be collected. On the contrary, the existing experimentally validated criteria of intrinsic disorder 
can be and have to be used for the creation of corresponding computational tools. These algorithms 
represent a very important addition to the researcher’s arsenal and open possibility for large scale 
analysis. One should remember that the interest to protein intrinsic disorder and appreciation of its 
importance for protein function was generated via the recognition that IDPs are not rare exceptions, 
but a new rule. Furthermore, this recognition was based on the bioinformatics and computational 
analyses, where various predictors of protein intrinsic disorder were used. 
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4. Multiparametric approaches for assessing intrinsic disorder: Experimental 
view on conformational ensembles and induced folding transitions 
 
Structural disorder can be detected and analyzed by many (bio)physical techniques, some indirect, 
others more quantitative in providing structural data. Among them, one of the most powerful in 
providing quantitative information is NMR. 
 
4.1. NMR 
 
NMR is widely recognized as the predominant, quantitative technique in studies of IDPs. This section 
will provide a description of the most broadly used NMR experiments and of the most recent NMR 
advancements that have enabled a transition from a qualitative to a quantitative description of 
IDPs.50  
 
A global characterization of IDPs can be inferred by either simply recording a one-dimensional 
spectrum (1-D) and deriving the information from the low spread of the proton resonance 
frequencies due to the presence of all the residues in the same environment, or by performing a 
wide-line NMR relaxation experiment that provides information about the presence of a large 
hydrate layer in agreement with a disordered, open and extended state. Additionally, using pulsed-
field gradient NMR, one can also measure the diffusion coefficient of proteins from which 
hydrodynamic parameters can be determined.42 Although these latter are less direct indicators of 
disorder as compared to chemical shifts, they provide useful hints because IDPs possess peculiar 
hydrodynamic parameters as compared to structure proteins. Heteronuclear single quantum 
coherence (HSQC) is one of the most frequent experiments in the IDP literature. It represents the 
starting point of resonance assignment (i.e. the process of identifying which resonance belongs to 
which residue of the protein), which is essential for a meaningful interpretation of more advanced 
NMR experiments. Indeed, high-field NMR spectrometers together with uniformly and specifically 
labeled proteins have overcome the problem of proton signal overlap of IDPs. Resonance 
assignments can be made using the dispersion of 15N and 13C nuclei, which are more sensitive to local 
amino acid sequence.51 Recently, methods exclusively based on 13C detection have been reported, 
which afford an independent strategy to simplify crowded spectra as well as to perform sequence-
specific assignment.52 HSQC experiments are also useful for detecting interactions with unlabeled 
binding-proteins, because a change in the chemical environment and in relaxation due to the 
interaction make NMR parameters of residues directly involved shift or even disappear from the 
spectrum.53 Once a resonance assignment has been achieved, a variety of NMR parameters can be 
determined to characterize the structural and dynamic behavior at the residue level, thus obtaining 
sequence-specific structural information (Fig. 6).  
 
In order to determine local secondary structural preferences, many methods have been described in 
the literature such as chemical shifts (which is the most powerful tool for achieving this goal), 
coupling constants (which are directly related to bone torsion angles) and short range nuclear 
Overhauser effect (NOEs) (which can be used to corroborate secondary structure propensities 
detected through chemical shifts).54  
 
The primary observable in NMR studies of unfolded and partly folded proteins is the chemical shifts 
that are sensitive to polypeptide backbone torsion angles. Deviation of chemical shifts from random 
coil values (termed secondary chemical shift, SCS, or chemical shift index, CSI) for 1Hα, 13Cα, 13Cβ, and 
13CO are sensitive to local secondary structure (i.e. population and location) and hence provide 
important insights into the structures populated in the conformational ensemble in IDPs.51,55,56 One 
potential problem associated with this kind of approach concerns incorrect frequency referencing, 
8  
 8 
which can result in systematic errors in the secondary shifts. In order to address this problem, the Cα 
and Cβ chemical shifts (that shift in opposing directions for α-helical segments) can be used 
simultaneously to estimate the level of secondary structure in disordered proteins.57 In Fig. 6B, an 
example taken from 58 is provided showing the 13Cα  chemical shifts of the intrinsically disordered C-
terminal domain of the measles virus nucleoprotein (NTAIL) both in its free and bound (i.e. in complex 
with the C-terminal domain of the phosphoprotein, XD) states. This enabled to reveal that the 
protein has a propensity to form an α-helix even in the free state.  
 
More detailed information about local conformational sampling can be derived from inter proton 
NOEs. However, quantitative interpretation of NOEs is complicated by the strong sensitivity of the 
interaction on the range of dynamic timescales commonly encountered in unfolded proteins.59 In 
addition, long range NOEs characteristic of tertiary interactions are usually not observed in IDPs due 
to fluctuations and heterogeneity of the structure.42 Another interesting parameter that one could 
infer from HSQC-based experiments is relaxation rates (such as 15N relaxation experiments) that 
reflect backbone and side-chains dynamics and could provide information about local disorder. 
Analysis of the relaxation data is particularly informative on local structural preferences, such as 
hydrophobic clusters, secondary structure elements and transient long-range contacts.54 In fact, 
variations in backbone mobility can be correlated with intrinsic properties of the amino acids in the 
sequence. Clusters of small amino acids such as glycine and alanine show increased backbone 
mobility, compared to the average. In contrast, local hydrophobic interactions that persist in urea 
cause some restrictions of backbone motions, hence supporting the fact that a RC never exists, not 
even under the harshest denaturing conditions (i.e., in solutions containing 8M urea or 6 M 
guanidinium chloride).60  
 
The above-listed traditional NMR parameters only provide information about the local dynamics and 
structural state. This situation has changed by the advent of methods based on residual dipolar 
couplings (RDCs) and paramagnetic relaxation enhancements (PREs), which yield a high number of 
well-defined quantitative parameters reporting on long-range interactions (PRE) and global structure 
(PRE, RDC).54,59,61,62  
 
PRE has been most successful in detecting long-range contacts in disordered protein ensembles. The 
method relies on the introduction of a paramagnetic nitroxide spin label at a specific position within 
the amino acid sequence.54 HSQC spectra are then recorded with the spin-label in the paramagnetic 
(oxidized) and diamagnetic (reduced) states, and differences in one of several parameters, such as 
line-width, relaxation rate, or intensity are determined. Limitations of this approach include the need 
of a number of cysteine-carrying mutants of the protein, and possible interference of non-native 
side-chain and/or the radical with native long-range contacts. Nevertheless, these measurements are 
extremely powerful, because they provide unambiguous evidence of the presence of fluctuating 
tertiary structure that can be very difficult to identify by other techniques.59 An example taken from 
ref.54 illustrating how a long-range distance could be inferred from PRE measurements is provided in 
Fig. 7. Moreover, many examples in the literature have used PRE distance information to constrain 
MD simulations and finally arrive at a reasonably confined distribution of structural states in the 
ensemble of IDPs.61,63 
 
As compared to chemical shifts and NOEs, RDCs present a powerful tool that provides a far more 
extensive and quantitative description of local, and possibly, global order in the unfolded state.55 
Indeed, RDCs measured between pairs of nuclei in partially aligned proteins, are very sensitive 
probes of time and ensemble-averaged conformational equilibria exchanging on timescales up to the 
millisecond and can therefore be used to characterize both the structure and the dynamics of 
unfolded proteins.59 An example taken from ref.62 showing how RDCs have been used to probe the 
level and nature of residual structure in the C-terminal region of the MeV nucleoprotein (NTAIL) is 
provided in Fig. 8A.  
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The unique power of NMR in characterizing IDPs is that the combination of different approaches 
enables to describe the real structure of IDPs; i.e., their structural ensemble, either alone or in the 
bound form.64 Indeed, recently the disordered C-terminal domain of the measles virus nucleoprotein 
has been studied by a combination of NMR spectroscopy, SANS (small angle neutron scattering) and 
electron microscopy (EM), providing an in situ ensemble model describing the conformational 
behavior of the disordered region at the surface of the nucleocapsid (see Fig. 8)62 (For further 
description, see section 5.3) 
 
In all, NMR provides quantitative residue-level information on structure and dynamics of IDPs, which 
enables to develop structural ensembles, the current best representation of the structure of IDPs. It 
should not be forgotten, however, that NMR has some inherent limitations, due to which it is best 
complemented by other quantitative biophysical techniques. Examples of such limitations, are 
averaging of fast exchange events, low signal/noise ratio, difficulty in defining ensemble shape and 
poor ability to provide information on global crossing between meta-stable sub-states, not to 
mention the fact that NMR is highly demanding in terms of protein amounts, that isotopic labeling is 
rather expensive and that some proteins are very poorly expressed in minimal media. 
 
 
4.2. Further quantitative techniques for characterizing structural disorder 
 
The limitations of NMR call upon complementing and/or combining its results with some other 
biophysical techniques which provide additional insights into the structural details of IDPs, and also 
enable approximations not yet amenable for NMR. Among these, we can cite for instance site-
directed spin-labeling EPR spectroscopy,65-67 an approach powerful in documenting and mapping 
structural transitions in IDPs, which is currently being expanded thanks to the introduction of a new 
generation of spin labels targeting residues other than cysteine.68,69 Concomitantly to experimental 
techniques, in silico approaches have also been developed that enable physical quantification of 
folding and binding energy landscapes of IDPs at atomistic level. Among them, we cite those 
established by the group of Jin Wang who developed an atomic hybrid model for IDPs by integrating 
local physics-based interactions and non-local structure-based interactions.70-72 In their recent 
approach, they have quantitatively uncovered the intrinsic energy landscape (not the free energy 
landscape often discussed in the field) of folding and binding. To this end, they have exlored the 
underlying density of states, which is a statistical distribution in microcanonical ensemble extracted 
from the conventional canonical ensemble binding–folding dynamics using a structure-based model 
both with and without considering energetic roughness. 71 To visualize the landscape, they chose the 
energy and the structural similarity of generated conformers to native structure defined as the 
fraction of native contacts as reaction coordinates. The authors showed that the energy landscape of 
folding and binding is funneled towards the native state. The energy landscape topography 
representing the degree of the funnelness is quantified by the dimentionless ratio of the slope and 
the roughness modularized by the entropy (size) of the funnel. The authors showed that this 
landscape topography ratio determines the thermodynamics, kinetics, and the association 
mechanism of the binding–folding dynamics. Using this newly developed IDP model in combination 
with physics-based simulations (with solvent), Wang et al. recently described the unbound 
ensembles of the α-MoRE (residues 484-504) located within the intrinsically disordered C-terminal 
domain of the measles virus (MeV) nucleoprotein (NTAIL) and deciphered the mechanism by which the 
α-MoRE recognizes the X domain (XD) of the MeV phosphoprotein.73 
 
Among experimental techniques providing quantitative information, SAXS and single-molecule 
approaches, which allow the observation of transient intermediates, have enabled a better 
understanding of the behavior of IDPs. In particular, SAXS studies, combined with ensemble 
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optimization methods (EOM), have led to low-resolution description of IDPs as realistic 
conformational ensembles (see ref.74 and references therein cited).  
 
In-bulk methodologies to studying IDPs, however, have two main intrinsic limitations. The first 
limitation is connected to the limited capability to single out the monomeric state of the investigated 
IDPs. In the experimental conditions, the monomeric state of the protein under study might easily 
co-exist along with soluble oligomers that can form quickly in solution at the concentrations required 
by the sample preparations. Single-molecule methods operating at low concentrations or with 
immobilized molecules allow the properties of the monomeric species to be monitored without any 
interference by aggregation already started. The second limitation of the traditional in-bulk 
methodologies is connected to their time and ensemble averaging. They can observe only average 
properties of 1014–1017 molecules at a time. Even in the case in which no oligomers are present in the 
sample, the intrinsic ensemble averaging of in-bulk methodologies might prevent to single out poorly 
populated states. Single-molecule (SM) approaches, such as high-speed atomic force microscopy (HS-
AFM),75,76 AFM-based force spectroscopy (FS),77 and fluorescence resonance energy transfer 
(FRET),78-80 therefore represent a powerful tool to investigate the structure and the dynamics of IDPs. 
While SM-FRET reports changes in the mean distance between two residues (steady-state FRET) and 
intramolecular distance distributions (time-resolved FRET) enabling to study conformational 
equilibria in timescales shorter than a few milliseconds, AFM-based SM-FS is particularly sensitive to 
the formation of secondary structures, and probes timescales from milliseconds to seconds, much 
longer than those of SM-FRET. 
 
HS-AFM allows direct observation of structural dynamics and dynamic processes of biological 
molecules, with a sub-second to sub-100 ms temporal resolution.75,81 Various dynamic protein 
processes have been successfully visualized by this approach. HS-AFM is not only applicable to well-
structured proteins but also to IDPs. The group of Toshio Ando was the first to use HS-AFM to directly 
visualize IDPs attached on a mica surface.76 
 
Altogether, conformational and spectroscopic studies carried out thus far have unveiled that IDPs do 
not represent a homogeneous structural class, and range from fully extended (random-coil like) to 
compact (molten-globule like) states. To accommodate all these states in a functional framework, 
Keith Dunker elaborated the Protein Trinity Hypothesis,82 which posits that a native protein can be in 
one of three states, the ordered state, the collapsed-disordered (molten globule, MG) state and the 
extended-disordered state (random coil, RC), and that function can arise from any of the three states 
or from transitions between them.82 This model was subsequently expanded to include the pre-
molten globule (PMG) state, which corresponds to an intermediate state between the RC and the 
MG (Fig. 9)13 (see also section 5.1).  
 
4.3. Complementary methods for studying protein disorder  
 
Certain low-tech approaches have provided ample early insight into the phenomenon of structural 
disorder, and paved the way for the general acceptance of this concept. Even today they may 
provide important insight and/or fast information on the structural state of a protein or its region. 
 
IDPs can be recognized by their peculiar biochemical behavior. Indeed, due to their amino acid 
sequence bias and the lack of a tightly packed hydrophobic core, the presence of disordered proteins  
is often apparent during the purification process. Owing to their unique amino acid composition, 
IDPs frequently bind less sodium dodecyl sulfate (SDS) molecules than globular proteins leading to an 
aberrant mobility in SDS polyacrylamide gel electrophoresis (SDS-PAGE). Their apparent molecular 
mass determined by this technique is usually 1.2-1.8-fold higher than expected from the amino acid 
sequence measured by mass spectrometry.11 Although this abnormal behavior has been ascribed in 
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the past to enrichment in acidic residues, recent findings suggest that other additional parameters, 
such as extension in solution, can be responsible for the abnormal electrophoretic migration of IDPs 
in SDS-PAGE.49 
 
An abnormal mobility is also observed in gel filtration (GF) or size-exclusion chromatography (SEC) 
experiments, in which IDPs have unusually high apparent molecular mass.12  
 
Furthermore, flexible regions are known to be highly susceptible to proteolysis. Thus, limited 
proteolysis can be used to distinguish ordered and disordered proteins, as an increased proteolytic 
degradation in vitro argues for increased flexibility. Early observations on the curiously protease 
sensitive behavior of proteins were made on bacteriophage λ N,83 dsp16 84 and p21,85,86 as outlined 
in general in refs.11,16,87   
 
A further special behavior of IDPs is their insensitivity to high temperatures and their stability 
towards acidic treatment, as observed early for MAP2,88 α-synuclein,89 involucrin,90 and caldesmon,91 
for example. These conditions usually causing the precipitation and/or denaturation of globular 
proteins,53 as often exploited in the purification of IDPs.92-94 These peculiarities of IDPs provide the 
first line of indirect evidence of their unusual structural state. Direct structural information, however, 
can be obtained by a wide variety of experimental approaches (reviewed in ref.95). 
 
 
4.4. Analyzing disorder in a living cell 
 
4.4.1. In vivo existence of protein disorder 
 
A major challenge in the field of IDPs is to assess to what extent in vitro observations on the 
structural state and function of IDPs can be extrapolated to the living cell. Indeed, concentrations of 
proteins and other macromolecules reach 300-400 mg/ml in the cell, giving rise to a crowding 
effect96,97 that could affect the structural state of IDPs.  Crowding might force IDPs to assume 
compact or even folded states caused by excluded volume effects, making this issue critical with 
respect to their physiological structural state and function. The presence of their binding partners 
might suggest that IDPs are partner-bound (and folded) most of the time. There are two direct 
approaches to address these issues: 1) mimicking crowding conditions in the test tube and 2) 
characterizing IDPs directly in the living cell. 
 
An ideal in vitro crowding agent combines three different effects: an excluded volume effect, an 
increase in viscosity and an influence on the solvation/hydration of proteins.  To mimic these, 
accepted approaches are to apply high molecular-weight (Mw) polymers, such as Dextran and Ficoll 
70, or small molecule osmolytes, such as sucrose, trifluoroethanol (TFE) or trimethylamine N-oxide 
(TMAO). The high-Mw polymers primarily exert excluded volume effect, whereas osmolytes primarily 
act upon solvation of the protein backbone.98 Osmolytes tend to stabilize function-related secondary 
structure of IDPs, as usually demonstrated by CD spectroscopy.53 Crowding by Dextran and Ficoll-70 
does elicit some compaction but not folding of IDPs,42,99,100 as demonstrated on different IDPs under 
different conditions and using a variety of techniques.101 It appears that the formation of local 
secondary structural elements of IDPs is promoted by crowding and thus preformed structural 
elements (PSEs) may receive even more credit than suggested by in vitro studies.42  
 
To obtain direct information from the cell, two approaches could be used: assessing proteasomal 
degradation and in-cell NMR studies. In the first approach, the ability of the 20S proteasome to 
degrade unfolded proteins is exploited. This degradation “by default” (i.e. ubiquitin-independent 
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degradation) provides evidence on the physiological structural status of proteins. It was used to 
characterize in vivo several IDPs including p53,102 and p21Cip1,103 for which the default degradation by 
the proteasome argues for their disordered state in the cell.  
 
The application of in-cell NMR requires the deposition of labeled proteins within the cell either by 
over-expressing under labeling conditions, by covalently linking cell-penetrating peptides to the 
protein, or by microinjecting it into the cytoplasm of the cell.42,104 An example is the tau protein that 
has been studied by in-cell NMR in Xenopus oocytes: while its microtubule-binding region became 
ordered, its long projection domain remained largely disordered.105 Very recently, the group of 
Michele Vendruscolo has reported a study where in-cell NMR spectroscopy was used to observe 
directly the structure and dynamics of α-synuclein within E. coli cells. In agreement with previous 
studies by the group of Philipp Selenko,106 the results indicate that, at least within the bacterial 
cytosol, α-synuclein populates a highly dynamic state that, despite the highly crowded environment, 
and it has the same characteristics as the disordered monomeric form observed in aqueous 
solution.107 α-synuclein was observed to be largely disordered in the periplasmic space of E. coli.108 
 
4.4.2. Survival of IDPs in the cell 
 
These observations raise the issue of in vivo degradation of IDPs, given their extreme proteolytic 
sensitivity in vitro.11 The work by Belle et al. in 2006, in which in vitro half-lives of 3,750 yeast 
proteins have been determined, made the analysis of in vivo protein degradation possible.109 By 
observing a limited correlation between half-life and predicted disorder, it was established that 
intrinsic disorder serves as a weak signal for intracellular degradation and the in–cell degradation is a 
multi-factorial process to which several signals including physical features, and regulatory 
mechanisms contribute.110 Further, it was found that the half-lives of proteins depend primarily on 
the length of the polypeptide chain, and hence on the number of potential cleavage sites. The 
observation that ubiquitinated proteins require disordered initiation sites for degradation,111 and 
that disordered proteins may be even directly degraded by the 20S proteasome without prior 
ubiquitination (i.e. degradation by default),112 is in line with this notion. Interestingly however, PEST 
regions (i.e. sequences of 10-50 amino acid residues that are enriched in Pro, Glu, Ser, and, Thr and 
that tend to turn over rapidly), destruction boxes and KEN-boxes (i.e. signal for a more specific 
degradation mechanism), are only poorly correlated with short half-lives.  
 
A corollary of this study is that IDPs might be well-protected in vivo by accessory proteins, such as 
chaperones. To address the role of chaperones in IDPs function in vivo , pairwise interaction data 
from high-throughput interaction studies were analyzed for the correlation between intrinsic 
disorder and chaperone binding.113 The finding that partners of chaperones tend to be ordered 
proteins suggested that IDPs need no assistance for folding and/or protection against degradation, 
but possibly only for assembly into complexes and against aggregation.113   
 
A related study by M. Babu and colleagues on the yeast and human proteomes showed that rather 
than a single regulatory mechanism, multiple mechanisms during transcription and translation 
control the availability of IDPs, and that IDPs do undergo a faster turnover as compared to globular 
proteins. Furthermore, the residence time (i.e. abundance, rate of synthesis, and half-lives of mRNA 
and proteins) of IDPs, in different organisms including human cells, was found rather low due to 
increased transcript clearance and proteolytic dégradation.114 The need of tight regulation of IDPs is 
probably explained by their noted “dosage sensitivity” which denotes genes that are harmful when 
overexpressed. Intrinsic protein disorder was found to be an important determinant for proteins 
encoded by these genes, and explained by their inclination to be involved in promiscuous molecular 
interactions.115 Regulation of dosage-sensitive genes occurs at the transcriptional, RNA, and protein 
levels.116 
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Recent studies by Suskiewicz and colleagues proposed several possible further mechanisms by which 
IDPs could be regulated in vivo,117 where IDPs would be protected from degradation by default (see 
Fig. 10) through interactions with partners. In fact, forming a functional complex in vivo provides a 
way to avoid degradation either by promoting order or by masking IDRs (Fig. 10A). Apparently, some 
binding partners interact with IDPs principally to prevent their proteolysis. Those partners could be 
proteasome gatekeepers (Fig. 10B) interacting with the 20S proteasome or nannies (Fig. 10C) that 
are usually more specific for particular IDPs. Moreover, IDPs can bind to DNA (Fig. 10D), (for instance 
IDPs functioning as transcription factors) or also to “decoy” binding sites (Fig. 10E) that can compete 
with functional regions for binding to transcription factors. On the other hand, IDPs make 
interactions with themselves also (Fig. 10F). In order to avoid proteolysis initiated by a disordered N-
terminus, an IDP could be stabilized by either a folded N-terminal domain (Fig. 10G), or by the 
interaction with ribosomal proteins (Fig. 10H) until a longer sequence is synthesized that could be 
stabilized by either a suitably nanny (Fig. 10C) or by a self-organization into a loopy structure (Fig. 
10F).117,118 These proposed mechanisms actually relieve chaperones from the duty of guarding IDPs.  
5. Structural and conformational characteristics of IDPs      
 
5.1. IDP structure from the polymeric physics viewpoint  
 
By definition, IDPs are devoid of stable secondary and/or tertiary structures under physiological 
conditions (please note that although collapsed IDPs, which are classified as native MG (see below), 
could contain some stable secondary structure elements, they still will be devoid of tertiary 
structure). Indeed, they consist of dynamic structures that interconvert on a number of timescales. 
However, a majority of them has some residual transient secondary structures that are required for 
function. Hence, it should be borne in mind that most proteins are neither fully ordered nor fully 
disordered but contain ordered and disordered regions at different ratios (Fig. 11).42,119,120 Indeed, 
only about 32% of the crystal structures of the PDB are completely devoid of disorder121,122 and the 
degree or the depth of disorder (as it is manifested by the absence of the electron density) vary 
widely, suggesting that the fully ordered protein depicted in Fig. 11 is apparently the exception 
rather than the rule.119 In addition, numerous experimental examples in the literature argue for a 
continuum of disorder rather than a unique disordered state, as suggested in ref.123 
 
Depending on the content of residual structure and environment, IDPs may exist in at least three 
separate functional conformations: molten globule (MG), pre-molten globule (PMG) and random 
coil-like (RC-like).13 In fact, IDPs can attain extended conformations (RC and PMG) or remain globally 
collapsed (MG) (Fig. 12, see also section 4.3)  
 
The collapsed disorder comprises the MG state, in which native secondary structures exist although 
the protein molecule lacks well-packed core. MGs are characterized not only by the well-developed 
secondary structure, but also by the presence of some topology, i.e. relatively fixed mutual 
positioning of the secondary structure elements, and a compact state close to that of ordered 
globular proteins.13 The considerable increase in the affinity for hydrophobic fluorescence probes 
(ANS, for instance), the accessibility to proteases and the increase in the hydrodynamic radius which 
corresponds to a volume increase of approximately 50% with respect to that the native globular 
state, are diagnostic markers of the MG state.13 Recent analyses of IDPs by the group of Pappu 
indicated sequence polarity and distribution of charged residues as determinants of IDP compaction: 
indeed polar IDPs were found to favor collapsed ensembles in water despite the absence of 
hydrophobic groups.124,125 
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Extended disordered proteins also should not always be considered random coils. For practical 
reasons, they can be divided into two separate sub-families,13 PMG and RC conformations. The PMG 
state can effectively interact with the hydrophobic fluorescent probe ANS, though more weakly than 
a MG, which suggests that some hydrophobic clusters are formed in this state. Therefore, the PMG 
probably represents a “squeezed” and partially ordered form of the coil with some residual 
secondary structure.126 The RC, or rather, RC-like, state has hydrodynamic dimensions typical of 
considerably unfolded polypeptide chains that are devoid of any ordered secondary structure.13  
 
In general, PMGs are somewhat enriched in hydrophobic residues and have regions corresponding to 
residual secondary structure, which can be pointed out by HCA analysis indicating regions with a 
potential for induced folding (see section 3.2). It should be noted however that the content in regular 
secondary structure is not a major determinant of protein compaction.49,127,128 
 
5.2. Evaluating residual structure in IDPs  
 
The hydrodynamic volume of a single-domain globular protein in the MG, PMG and the unfolded 
state, typically increases 1.5,   ̴3 and   ̴12 times, respectively, in comparison with that of the native 
state.129,130 Hence, several techniques such as GF, small angle X-ray scattering (SAXS), analytical 
ultracentrifugation and dynamic light scattering (DLS), to name a few, may help in determining 
whether a protein is collapsed or extended due to the difference in its hydrodynamic properties (Fig. 
12).13 An empirical formula connecting the Stokes radii (RS) to the apparent molecular masses 
(appMM) of proteins in different conformational states deduced from GF analysis enable to 
distinguish between the various protein conformations (Fig. 12).12,13,95 Residual structure in IDPs can 
also be unveiled by measuring the increase in hydrodynamic properties using DLS or SEC upon 
heating or chemical denaturation.95  
 
The residual structure in IDPs can also be unveiled by spectroscopic techniques such as circular 
dichroism (CD).131 The unfolded polypeptide chain is characterized by an intensive minimum in the 
vicinity of 190 and 200nm and an ellipticity close to zero in the vicinity of 222 nm (Fig. 13A).53 
Consequently, the estimation of the secondary structure content allows MGs, with stable secondary 
structures, to be distinguished from RCs or PMGs (Fig. 13A). To discriminate between the extended 
states (i.e. PMG or RC) a “double wavelength” plot plotting the mean residue ellipticity at 222 nm as 
a function of the mean residue ellipticity at 200 nm, was developed by Uversky  (Fig. 13B).13,95 
Discrimination can also be improved by applying denaturants and/or heating the protein, and by the 
simultaneous use of CD and hydrodynamic techniques or by the combined use of near-UV CD.13  
 
Interactions between multivalent IDPs may lead to the formation of higher-order structural 
organization, as demonstrated by sharp liquid-liquid-demixing phase separations, generating 
micrometre-sized liquid droplets in aqueous solution. This macroscopic transition corresponds to a 
molecular transition between small complexes and large, dynamic supramolecular polymers, with 
the valency of the interacting species being directly related to the concentrations needed for phase 
transition. Importantly, phase transitions can be related with changes in protein activity and can be 
governed by posttranslational modifications (PTMs), as shown in the case of the actin-regulatory 
neural Wiskott-Aldrich syndrome protein (N-WASP).132 The widespread occurrence of multivalent 
systems suggests that similar phase transitions may be used to spatially organize and biochemically 
regulate information in biological processes.133 
 
5.3. IDPs as conformational ensembles 
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The full structural description of IDPs is only feasible by ensemble approaches, primarily based on 
NMR observables, such as chemical shifts (CSs), Residual Dipolar Couplings (RDCs), 15N R2 relaxation 
rates, Paramagnetic Relaxation Enhancement (PRE) distance restraints, J-couplings, pulsed field 
gradient (PFG)-derived Rh values, and 1H-15N heteronuclear Nuclear Overhauser Effects (hetNOEs), 
complemented by SAXS, which all together yield detailed information on short- and long-range 
contacts and backbone flexibility.134-136 By all this information combined, one can describe the 
structure of an IDP as an ensemble of conformations. To this end, two broad approaches have been 
developed: either through restrained molecular dynamics simulations, or the generation of a large 
number of conformations and selection of a subset that fits the data.64  
 
In molecular dynamics simulations, the conformational space accessible to a given protein is sampled 
by penalizing deviations between the experimental data and the corresponding values back-
calculated from the structures sampled during the simulations.63 It should be noted that there is no 
guarantee that the generated structural ensemble would be consistent with experimental data not 
used as restraints. This is a general consequence that we cannot measure sufficient number of 
restraints at the moment.64,137 
 
The second approach starts with generating a very large pool of conformations, which may be 
completely random or constrained by experimental or theoretical data (e.g. Ramachandran Ψ/Φ 
angles taken from coil regions of PDB structures). Programs such as Flexible-Meccano,138 Ensemble 
Optimization Method,135,139 and TRaDES140,141 are currently used for this purpose. If not provided by 
the initial algorithm, side chains can be modeled in with an algorithm such as SCCOMP142 or 
SCRWL.143 Expected experimental observables are then back-calculated for each conformation in the 
pool (with CRYSOL for SAXS,144 or ShiftX or SPARTA for NMR145). 
 
From the pool, a subset of structures (on the order of 50-100) is selected through step-wise 
optimization until the best fit is achieved. The ensemble describes the conformational state of the 
IDP, to the limit of the amount and quality of experimental data. Obviously, one of the most 
important issues in IDP research is to define the number (or range) of conformers for such ensembles 
to be relevant. Although this can only be addressed by performing the corresponding computational 
experiments, we expect the size of the ensemble to be roughly proportional to the extent of disorder 
in a given protein. It is also possible that the size of the ensemble can depend on the particular type 
of IDP function. Recent analyses revealed that in most cases 50-100 structures in the ensemble 
suffice in describing experimental observations 59, and even in large (such as α-synuclein and tau) and 
highly extended (p53TAD) disordered proteins, their conformational ensemble can be reliably 
described by about 200-400 members.146,147  
Ensembles can be deposited in the newly developed protein ensemble database (pE-DB, 
http://pedb.vib.be), which hosts primary experimental data, algorithms used for calculation and 
ensembles for IDPs.148 Because ensemble are not unequivocally defined by structural data available, 
one protein can have several ensembles, and it is the major aspiration of the IDP field to find out 
how relevant ensembles are, i.e. if the function of IDPs can be interpreted by the ensembles. If we 
achieve this goal, it will signal the dawn of a new era in unstructural biology.149 
 
5.4. Electrostatic and charge effects of compaction of the structural ensemble of 
IDPs  
The structural ensembles of IDPs have many features, local and global, which are critical for the 
functioning of the protein.149 Local features such as the presence of pre-structured motifs might be 
involved in mediating interactions with partner proteins, whereas global hydrodynamic features 
might be important in regulating accessibility/exposure of motifs and also long-range communication 
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between different parts of the protein. Recent advance in describing IDPs by polymer theories offers 
a much improved insight into the sequence determinants of their global structural organization.  
 
These theoretical and experimental approaches are derived from recognizing that despite a paucity 
of hydrophobic residues, polar/charged residues in IDPs prefer their collapsed structures in aqueous 
milieu.150 Many of these analyses suggest that water at ambient temperatures is a poor solvent for 
generic polypeptide backbones, which makes IDPs in general to compact, with electrostatic 
interactions having a basic influence on the final state.124 A study of highly charged IDPs by molecular 
simulations and fluorescence approaches showed that the charge content and pattern modulate the 
intrinsic preference of polypeptide backbones for collapsed structures. It was found that net charge 
per residue serves as the major discriminating order parameter, also in line with previous 
suggestions that net charge is a primary determinant not only of protein disorder15 but of the 
extension of IDPs.151 In addition, although overall amino acid composition represents a good proxy 
for polymeric properties, fine details of conformational ensembles depend on specific sequence 
attributes. 
 
This is particularly true for the net charge of the polypeptide chain. Most IDPs are polyampholytes, 
i.e. their sequences include both positively and negatively charged residues. The fraction of charged 
residues discriminates between weak and strong polyampholytes, and weak polyampholytes tend to 
collapse into compact states.125 The conformational preferences of strong polyampholytes, on the 
other hand, are determined by both the fraction of charged residues and the sequence distribution 
of oppositely charged residues. In the case of well-mixed sequences, electrostatic repulsions and 
attractions within the chain are counterbalanced, leading to a preference to a self-avoiding random 
walk or generic Flory-type random coil conformational state. When oppositely charged residues are 
segregated within the sequence, hairpin-like conformations emerge because long-range electrostatic 
attractions are preferred. It was also observed that the naturally occurring polyampholytes are 
usually well mixed, with a preference for random-coil ensembles. These inferences have been further 
born out by FRET experiments, which show that IDPs exhibit expansion at low ionic strength that 
correlates with their net charge.152 Charge-balanced polypeptides exhibit an additional collapse at 
low ionic strength conditions, yet they show low internal friction, which may have a significant 
impact on reconfiguration time.153 Reconfiguration time is particularly relevant for the kinetics of 
conformational reorganization, which is directly linked with the dynamics of the interactions of IDPs 
with cellular binding partners. 
 
 
5.5. IDPs, their environment and functional misfolding 
 
Noteworthy, many examples in the literature pointed out that the structure of IDPs is very sensitive 
to their environment, often displaying an inside-out behavior, i.e. a partial folding of IDPs with 
increasing temperature or increasing/decreasing pH.13,154-156 Indeed, this behavior makes perfect 
sense: increasing the temperature can increase the strength of the hydrophobic interactions leading 
to a stronger hydrophobic driving force for partial folding, whereas variations in pH minimize the 
large net charge present at neutral pH and consequently decrease the charge/charge intramolecular 
repulsion and thus shift the conformational ensemble towards more compact states.13,53 
 
Intriguingly, some regions cross the disorder/order boundary or assume different structures as a 
result of slight environmental changes. This “ambiguous” behavior has been addressed via two 
concepts, Chameleon Sequences157 and Dual-Personality (DP) sequences.158 While chameleon 
sequences fold in a template-dependent manner and could change conformation within the same 
protein as a result of point mutations, ligand binding or a change in pH, DP fragments are close to the 
order/disorder boundary. Owing to DP fragments, identical proteins solved in different conditions 
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and functional states can be captured in both conformational states: ordered and disordered. DP 
sequences possess an amino acid composition intermediary between ordered globular and 
disordered proteins. DP fragments are thus defined as a distinct structural category.42 When IDPs 
appear to have the capacity to adapt to the structure of distinct partners and to carry out different, 
occasionally opposing functions, the concept is denoted as “moonlighting”.159  
 
Finally, how does Nature prevent highly promiscuous IDPs from undergoing unwanted interactions 
with non-native partners? Interesting findings by Uversky160 suggest that IDPs escape unwanted 
interactions via functional misfolding (i.e. via the formation of non-native intramolecular 
interactions). In fact, since binding of IDPs to partners is frequently driven by hydrophobic residues 
organized in patches, the occurrence of PSEs with a non-polar continuous surface will surely promote 
the mutual attraction of these regions within the IDP and the formation of a structure where these 
elements are oriented to each other according to their interacting surfaces. In other words, the 
formation of native-like functionally relevant secondary structure elements containing sites for 
specific binding of native partners has to be accompanied by partial compaction of a polypeptide 
chain due to non-native intramolecular interactions (i.e. misfolding), thus native binding sites will no 
longer be exposed to interact with non-native partners.  
6. Intrinsic disorder and protein function      
 
6.1. Functional diversity of IDPs through the prism of structural plasticity 
 
The ultimate goal of the structural description of IDPs is to elucidate and rationalize the types and 
modes of functions they play. Functions of proteins can be classified according to the cellular 
processes they are involved in (Biological Process, BP) and their mode of action at the molecular level 
(Molecular Function, MF). Here we will outline the basic molecular modes of IDP functions, from a 
mechanistic perspective. Initially, IDPs were suggested to fall into 28 different mechanistic types.161 
In this classification, biological processes and molecular functions were not distinguished, and it was 
later shown that the actual functional modes can be rationalized in terms of five11 to six broad 
functional modes, as illustrated in Fig. 14. 
 
Entropic chain constitutes the first class where function involves no coupled binding and folding, 
rather it directly depends on the flexibility and the plasticity of the backbone. Indeed, the function of 
linkers and spacers, entropic clocks, entropic springs and entropic bristles stems directly from the 
disordered state. The microtubule-associated protein2 (MAP2), which functions as a spacer in 
microtubule architecture162 and FG Nups, which function as size-dependent filtering devices of the 
nuclear pore163 are appropriate examples for this functional mode.  
 
In the other classes, IDPs function via molecular recognition and hence they bind to a target, which 
could be DNA, RNA, another protein or a small ligand. When binding of the IDP alters the action of 
the partner (as, for instance, inhibitors or activators), the IDP belongs to the second class, termed 
effectors. Well-characterized IDPs in this class are p21Cip1and p27Kip1 that inhibit the cyclin-
dependent-kinase 2 (Cdk2) by binding to the Cyclin A-Cdk2 complex 164,165, and FlgM, the inhibitor of 
sigma28 transcription factor in bacteria 166. p21Cip1 and FlgM were the first IDPs to be studied in 
detail, which has lead to concepts such as folding induced upon binding, pre-existence of binding-
competent secondary structure and structural adaptability. Similar observations have been made 
with inhibitor 2 (I2) binding to, and inhibiting protein phosphatase 1.167,168 Effector functions of IDPs 
are probably the most straightforward to interpret in terms of the classical structure-function 
paradigm because the resulting complexes are often found in the PDB. When the effector has both 
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activities, activator and inhibitor, sometimes with the same partner, the term “moonlighting”169 is 
used (see also section 5.5).  
 
The third class is that of scavengers, in which the IDP stores and/or neutralizes small ligands. In fact, 
the open and extended structure of IDPs is particularly suited to bind small ligands, such as ions and 
organic compounds, either for disposal or for sequestration and later release upon the need of the 
organism.42 For example, salivary proline-rich glycoproteins, which constitute about two-thirds of the 
total protein in saliva, are scavengers that neutralize polyphenolic plant compounds (i.e. tannins).170 
Biomineralization proteins storing and delivering calcium/phosphate to the site of the buildup of the 
mineral phase in bone and teeth also exemplify this mode of action.171 
 
The fourth class constitutes assemblers, which assemble, stabilize and regulate large multiprotein 
complexes such as ribosome, cytoskeleton and chromatin.11 In agreement, both prediction and 
structural data show statistically significant correlations between disorder and either the number of 
protein subunits of complexes42,172 or established scaffold function.173,174 In addition, high disorder 
also appears in hub proteins.175,176 In interactomes, a few proteins possess a large number of 
connections (i.e. hubs), whereas most others have very few, often only one, connection. This 
arrangement suggests a functional specialization in which hubs are preferentially involved in 
organizing the network. Interestingly, a range of bioinformatics studies suggests that hub proteins 
have an elevated level of disorder (reviewed in ref.177). For example, Elisar Barbar and colleagues178 
describe how dynein light chain (LC8) interacts with multiple partners, many of which are not 
connected with dynein or microtubule–based transport, the function that was first attributed to this 
protein.178   
 
A special case of molecular recognition is exhibited by the fifth class, display sites, which mediate 
regulatory PTMs, such as phosphorylation or limited proteolysis. PTM of proteins has three structural 
requirements: an appropriate local sequence, structural exposure, and flexibility of the site so that it 
can be productively accommodated by the active site of the modifying enzyme; these requirements 
are met by structural disorder. Indeed, computational and experimental evidence support the 
abundance of PTM such as phosphorylation179 and ubiquitination180 sites in disordered regions of 
proteins. In addition, a recent study suggests that IDPs in yeast are more likely substrates of a large 
number of kinases.114 The power of DisPhos (disorder-enhanced phosphorylation) in predicting 
phosphorylation sites 179 revealed that phosphorylation sites primarily occur in regulatory, cancer-
associated and cytoskeletal proteins, as opposed to proteins involved in degradation, biosynthesis, 
and metabolism, a feature associated with protein disorder from early on.179 
 
A recent addition to the list of functional modes of IDPs is chaperone function.  A bioinformatics 
analysis showed that a high proportion of residues in RNA (54.2%) and protein (36.7%) chaperones 
fall into locally disordered regions.181 In addition, certain chaperone proteins are disordered along 
their entire length, e.g. α-synuclein,182 β-casein,183 or LEA proteins,184,185 or chaperone activity is 
localized to disordered segments, such as in the small heat-shock protein (Hsp) α-crystallin).186,187 
Disordered regions in chaperones can bind different partners (i.e. promiscuity), enable an enhanced 
speed of interactions and uncouple specificity from binding strength, which makes sense as 
chaperones need to bind a wide range of unrelated misfolded substrates. Moreover, the highly 
hydrophilic character of IDRs affords a solubilizing effect, preventing their aggregation42,181 as 
demonstrated by fusing disordered segments to a range of aggregation-prone proteins in expression 
studies.188 To accommodate all different aspects of the mechanism of action of disordered 
chaperones, an “entropy transfer” model has been suggested, in which transient binding, 
solubilization and entropic exclusion elements are blended with transient interaction with the 
misfolded region of the substrate (client).181  
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The role of disorder in chaperone action has been most convincingly demonstrated in the recent 
example of the redox-regulated chaperone Hsp33.189  This chaperone, which protects organisms 
against oxidative stress, is inactive in its fully folded state, but it undergoes oxidative unfolding within 
its redox-sensor domain upon stress. The IDR thus generated is used to discriminate between 
unfolded and folded partners. Upon returning to normal conditions, Hsp33 returns to the folded 
state and transfers bound clients to ATP-dependent foldases, i.e. its activity depends on internal 
order-to-disorder transitions. 
 
6.2. Short recognition motifs in the interactions of IDPs. Interaction networks, one-
to-many and many-to-one binding 
 
As also apparent from the foregoing classification, IDPs often function via molecular recognition, 
when they bind partner molecules in and induced folding process. Their mode of binding is thought 
to confer many advantages, and is often mediated by short recognition elements (motifs).190,191  
 
Different concepts regarding short recognition elements have been extensively discussed in the 
literature. Indeed, depending on whether the idea is approached from a structural point of view or 
defined at the sequence level, a short motif could be denoted as “Molecular Recognition Element” 
(MoRE) / “Molecular Recognition Feature” (MoRF)192 or “Linear Motif” (LM), respectively (LM is also 
denoted as “Eukaryotic Linear Motif” (ELM) or “Short Linear Motif” (SLiM)).193  
 
Moreover, Fuxreiter et al. in 2004 elaborated the concept of preformed structural elements (PSEs) 
correlating the probable structural preferences of IDPs in the unbound state.194 The structure of the 
recognition element of an IDP in complex with its partner is often known, and comparison of 
structures adopted in the bound form and that observed (or predicted) in the free form suggested 
that IDPs have rather strong intrinsic preferences for the conformation they attain when bound to 
their partners, with these preferences being highest for α-helical conformations. This may be 
interpreted in terms of partial pre-formation of their recognition segments in the free state.194 
Indeed, often a similar structure in the unbound and bound states is observed when the IDP is 
characterized by NMR, which formed the basis of the related concept of Pre-structured Motifs 
(PreSMos).195  
 
In a similar vein, MoREs/MoRFs has been established as short regions of (predicted) disorder that 
became structured and thus deposited into PDB, in complex with their partner. MoREs/MoRFs can 
adopt α-helix, β-strand or irregular secondary structure conformations (leading to α-, β- and I-
MoREs, respectively) or a combination of different secondary structural forms (complex-MoREs) (Fig. 
15).192 Although an exact relationship has not yet been systematically tested,196 it is appealing to 
assume that MoREs/MoRFs could correspond to PSEs. Repartition of secondary structures, which 
suggests significant differences between structures of IDPs in the bound state and those of globular 
proteins, supports this similarity. Indeed, secondary structure statistics on 26 IDRs in complex with 
their partners and on a reference dataset of globular proteins revealed that helices are almost 
equally populated in both datasets. On the other hand, β-structures in IDPs are about 50% less 
frequent than in globular proteins. The most significant difference is the increased level of coil 
conformation in bound IDPs. The analysis of the distribution of secondary structures in 
MoREs/MoRFs in the PDB is in complete agreement with these findings: such short binding elements 
have 27% of their residues in α-helical conformation, 12% in β-strands and approximately 48% in 
irregular conformations (13% missing from the atomic coordinates).20,42,197,198 
 
Molecular recognition by short recognition elements (motifs) can - and has been historically - 
approached from the completely different direction of short sequence patterns determining 
functional interactions and enzymatic modification, i.e. LMs, ELMs, and SLiMs.190,199,200  These motifs 
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are linear in the sense that 3-D organization is not required to bring distant segments of the molecule 
together to build up the recognizable unit.193 Disorder prediction of LMs and their flanking regions 
for the experimentally characterized examples of the ELM database (a database gathering Eukaryotic 
linear motifs) (http://elm.eu.org)199 suggests that LMs and their flanking regions are segments of 
intrinsic disorder within a more ordered environment.191 Their inherent flexibility probably allows 
them to adopt various conformations and to bind to multiple partners. LMs, however, are enriched 
in hydrophobic residues (Trp, Leu, Cys and Tyr), charged Arg and Asp, and Pro residues, and they are 
depleted in Gly and Ala. This could be explained by the fact that their restrictive sites (RS) directly 
involved in recognition are either hydrophobic and rigid, or charged and flexible, whereas at the non-
restrictive sites (NRS), excessive flexibility, even exceeding average IDPs, can be observed.42,190,191 
Overall, the unique amino acid composition suggests a mixed nature of LMs, with a few specificity-
determining residues strongly favoring order grafted on a completely disordered carrier sequence 
flanking the region critical for interaction.42  
 
Although not fully substantiated,201 the three concepts of short recognition motifs (PSEs, LMs, 
MoREs) can probably be considered as manifestations of the same underlying principle of binding of 
an ordered partner by a short segment within a disordered region, which undergoes a disorder-to-
order transition or induced folding upon binding.202 All the recognition motifs are short, on the order 
of 3 to 20 residues in the case of LMs,191 4 to 15 for PSEs, and less than 30 residues in the case of 
MoREs.20,159 Moreover, they possess an amino acid composition that resembles that of IDPs with 
some notable deviations (i.e. specificity-determinant residues favoring order) and they can even in 
some cases be already preformed in the free state (PSEs, PreSMos).191,193-195  
 
It is to be noted, however, that binding regions within IDPs might correspond more to a domain than 
a motif, with their length exceeding 20-30 residues.203 Indeed, these regions possess typical 
characteristics of domains: 1) they are structurally and functionally independent of the remainder of 
the protein molecule, 2) they can be recognized by homology due to evolutionary conservation of 
sequences,204-206 and 3) they possess at least one specific function. In fact, about 14% of Pfam 
domains (i.e. conserved evolutionary domains gathered in the Pfam database) selected from the 
SwissProt database possess more than 50% of predicted disorder and 4% are fully disordered.    
 
Due to their functional importance, predicting recognition elements (motifs) from sequence is of 
great interest. Although the information content of short sites is very limited, due to their 
enrichment in hydrophobic residues, indirect techniques have some success in delineating them. As 
mentioned, for example, the HCA plot43 (see section 3.2), can indeed unveil such binding sites.25 The 
PONDR VL-XT,23 ANCHOR (http://anchor.enzim.hu )207 and DynaMine208 disorder predictors are 
sensitive to local tendency of ordering, and are thus informative in highlighting potential induced 
folding regions. In the case of PONDR VL-XT, it was shown that there is a correlation between 
downward spikes in disorder scores and binding regions within IDRs.192 On the other hand, ANCHOR 
relies on the pairwise energy estimation approach (e.g. the approach of IUPred, see section 3.1) 
which identifies segments that are in disordered regions and cannot form enough favorable intra-
chain interactions to fold on their own and are likely to gain stabilizing energy by interacting with a 
globular protein partner.209 Although motif discovery from sequence alone is fraught with extremely 
high false positive rates, inclusion of additional data, such as enrichment in functionally related 
proteins, can significantly increase its confidence, as demonstrated in the SLiMDisc approach (for an 
example see ref.200). Furthermore, an ELM server (http://elm.eu.org/) has been developed in view of 
investigating short functional sites in modular Eukaryotic proteins.199 The recently developed 
dynamics predictor, DynaMine,208 shows that recognition motifs have characteristic patterns of local 
dynamics, which could be used for improving the accuracy of motif prediction. 
 
21  
 21 
6.3. Variability of binding modes attainable by disordered proteins: folding before 
or after binding      
 
It is currently accepted that the crux of the binding of IDPs is binding-induced folding, which can 
occur between an IDP and a globular partner, but also between two IDPs, with the resulting 
complexes often being amenable to structural studies.202 It is of significant interest whether folding 
occurs before, after or concomitantly to binding since experimental evidence seems to support all 
these varieties. NMR, molecular dynamics (MD) and site-directed mutagenesis are approaches to 
study the folding and binding events.42 Although conformational selection requires that the IDP 
populates at least partly the bound state in the free form, which therefore presages the final bound 
conformation,194,195 it is important to emphasize that the pre-existence of folded structures in IDPs 
does not necessarily imply a conformational selection mechanism.73,210,211 To further complicate the 
scenario, many IDPs show a high degree of adaptability with respect to the partner (Fig. 16), i.e. they 
can fold into different structures on binding to different partners. This plasticity raises questions 
about the role of PSEs in the recognition process, and suggests that the conformation sampled in 
solution will not necessarily be favored upon binding to a partner;212,213 i.e., there seems to be no 
general mechanism for the binding-induced folding of IDPs.42 Altogether, and in spite of recent 
breakthroughs, our understanding of the molecular features that encode the binding efficiency of 
IDPs is far from being elucidated and still matter of controversies (see ref.214 for a review on this 
topic). 
 
Generally, one should note that a major functional consequence of induced folding is a decoupling 
between specificity and affinity (i.e. binding strength) to enable weak and reversible interactions (Fig. 
17).192 In contrast with interactions involving globular proteins, where specificity and affinity are 
often coupled,192 when binding involves disorder-to-order transitions, entropy becomes a main 
factor in the free energy of binding, and the large decrease in conformational entropy uncouples 
binding strength from specificity, which makes highly specific interactions reversible.159,192 To limit 
unfavorable effects on binding and ensure kinetically and energetically “facile” interactions between 
IDPs and their physiological partner(s),194 the “conformational selection” model was proposed, in 
which pre-existent native-like conformations dominate the binding process.215,216 It is however to be 
expected that some degree of conformational adaptation will be required even when a preformed 
structural element in an IDP binds to its target.212 On the other hand, unlike “conformational 
selection”, much experimental evidence in the literature proposes that folding of IDPs can only take 
place upon binding and hence contacts (usually hydrophobic) with the binding-partner constitute the 
major driving force for the folding.202,212 In fact, recently, Phi-value analysis developed to study the 
mechanism of folding of globular proteins217,218 has been implemented in the IDP field. By this 
technique, residue-specific structural information is inferred by comparing the kinetics of the 
reaction (folding and/or binding) of the wild- type protein with a series of conservative single 
mutants, probing the presence of native-like structure in the transition state. Detailed kinetic and 
thermodynamic analysis showed that IDPs may bind both by conformational selection and induction 
of folding in the bound state.219-222  
 
Primary binding via an extended, disordered state, is the key element of the so-called “fly-casting” 
binding mechanism.223,224 It was assumed that IDPs can have an enhanced capture radius for a 
specific binding site, which confers an effective enhanced ability to search for a partner (also termed 
protein fishing).224 This mechanism is closely related to another concept of recognition by short-
motifs, that of “Primary Contact Sites” (PCS), which derives from the observation that IDPs can often 
attain the bound state very rapidly, suggesting that certain regions within their fluctuating structural 
ensemble might be exposed for initiating a productive interaction with the partner.42,225  
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It appears that the three mechanisms “conformational selection”, “induced folding” and “fly-casting” 
can be merged into a single “synergistic model”, in which all these elements synergistically 
participate. A brief description of such a consensus mechanism from ref.226 is provided (Fig. 18): the 
first step can be described as the non-specific reeling of the IDP by its target molecule via a “fly-
casting” mechanism. Once the IDP is close enough to its target, specific encounter is facilitated by 
PSEs, and “conformational selection” comes into play. Full formation of the complex, largely 
dominated by the folding coupled to binding, constitutes the third and last step of the consensus 
mechanism. The driving force of binding is provided by both the favorable intermolecular interaction 
energy and restriction of conformational entropy by binding conformationally restricted PSEs.226 An 
excellent example studied by NMR and MD experiments is the pKID and CBP complex 
formation.227,228  
 
It is of note, however, that in some complexes the binding does not induce folding. In such “random 
complexes”, the IDP interacts with its partner via transient contacts, and it behaves similar to its free 
form. This mechanism seems to operate in the C-terminal domain of the full length E. coli SSB that is 
disordered even when bound to DNA,229 and in T-cell receptor cytoplasmic tails forming homo-
oligomers without assuming a folded state.230,231 A similarly high flexibility in the bound form was 
also observed in the complex between the C-terminal disordered NTAIL domain of the nucleoprotein 
and the X domain (XD) of the phosphoprotein from Hendra virus, where the resonance behavior 
suggests α-helical fraying of the MoRE of NTAIL on the surface of XD.232 This binding via a disordered 
state has been termed “fuzziness”159,233 (see section 6.4).  
 
The chemical nature of the interface of IDP complexes also constitutes an area of interest. Indeed, it 
has been shown that the chemical and physical features of interfaces of IDPs are distinct from those 
of globular proteins in four major aspects.198,234 
 
1) Geometric particularities. IDPs use a large proportion of their surface for interaction with their 
partner (50% for IDPs whereas globular proteins use 5%-15% only).234 In terms of absolute values, 
however, the interfaces of IDPs are slightly smaller than those of ordered complexes (1141 ± 110 Å2 
for IDPs 234 versus 1600 ± 400 Å2 for globular proteins,235) which stems from distinct interaction 
topologies, i.e. from the fact that in 70% of the cases the binding surface of the IDP represents a 
sequentially continuous segment, and it never contains more than three separate segments. Ordered 
proteins, on the other hand, hardly ever use a single segment for binding to their partner, and their 
segmentation number may occasionally even exceed 10. It has been inferred that these differences 
might also be relevant for the weaker interactions of IDPs that might also entail less specificity.236,237  
 
2) Chemical nature of interfaces: buried versus exposed residues. The ratio of buried-to-exposed area 
of IDPs is much smaller for both polar and hydrophobic residues, which suggests that IDPs keep even 
their very few hydrophobic residues exposed for contact with the partner. In addition, interfaces of 
complexes involving IDPs were found to be enriched in hydrophobic residues, with these latter 
contributing significantly to the stability of the interaction interface.234 In a recent study, although 
enrichment in hydrophobic residues was confirmed, polar interactions were found to play a larger 
role in these complexes than in structured protein complexes, with interfaces being more 
complementary with respect to electrostatics than interfaces of globular proteins.238 
  
3) Interaction energies at the interface. Ordered proteins tend to establish more stabilizing 
interactions within their polypeptide chains, whereas IDPs derive more stabilization from the 
interaction with the partner.234 These features are also in line with the noted chemical nature of the 
interface, the higher ratio of hydrophobic amino acids and tighter fit, which compensate for the 
larger unfavorable decrease in entropy that occurs in folding induced upon binding. 
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4) Conservation of interfaces. The regions that become ordered upon complex formation in IDPs are 
the most conserved,234 in contrast with the general tendency of evolutionary variability of IDPs.239 In 
fact, interface positions show the most pronounced tendency to be conserved, in complete line with 
their functional importance, which helps their identification from sequence as linear motifs.240 
 
All these findings are in line with the exposure of hydrophobic amino acids in ELMs191 and MoRFs198 
and their tight interactions due to a better adaptation to the structure of the partner enabled by 
their induced folding. Recently, it has been confirmed that aromatic-aromatic intermolecular 
interactions in complexes implying IDPs occur frequently at the interface of the complexes, which 
provide both specificity and stability to the complexes and are enthalpically favorable.241 
 
6.4. Dynamic or fuzzy complexes 
 
In spite of the insight provided by the folding coupled to binding concept, ordering of IDPs is very 
often not complete even in the presence of the partner, i.e. the protein remains partially disordered 
in the bound state (Fig. 19). This led Tompa and Fuxreiter to coin the term “fuzziness”,159,233 which 
represents an extension of the concept of disorder in the bound state.159,242 
 
Apparently, this phenomenon presents a widespread novel paradigm of protein structure and 
function as supported by a dozen of IDP-complex examples gathered and described in detail,201,233 
pointing to the abundance of fuzziness in IDP-complexes. Fuzziness may mean only static structural 
promiscuity, when the IDP has more than one stable bound states, or it may encompass 
dynamic/disordered parts of the bound IDP. A linker region connecting two binding regions, or a 
flanking region might remain disordered, sometimes even the entire IDP fails to acquire a stable 
structure, as observed in the case of the cytoplasmic domain of T-cell receptors.230,231   
 
Many functional advantages can result from “fuzziness”, including interactions with alternative 
partners and simultaneous interactions with different partners.42 Indeed, the residual plasticity often 
allows adaptation of the same motif to different partners, or a variable arrangement of the 
recognition motifs, which can mediate interactions with alternative partners (i.e. promiscuity). 
Moreover, the disordered tails in complexes serve for partner fishing with nonspecific, transient 
contacts, the first step in the above-proposed model for IDPs interactions.224 Fuzzy parts of the 
complexes can harbor regulatory PTM sites or they can mediate interactions with additional 
partners. They can even directly or indirectly interfere with (promote or inhibit) binding of the part 
that undergoes folding transition. An illustrative example is provided by a proline-rich segment of the 
myelin basic protein (MBP) that can bind to several SH3 domain-containing proteins.243 In addition, 
fuzziness provides a way to reduce entropic penalty thereby affording enhanced affinity. 
 
6.5. IDPs and posttranslational modifications 
 
PTMs of proteins are reversible or irreversible chemical changes of a polypeptide chain that occur 
after translation. PTMs range from the enzymatic cleavage of peptide bonds to the covalent 
additions of particular chemical groups, lipids, carbohydrates or even entire proteins to amino acid 
side chains. PTMs extend the range of amino acid structures and properties, and diversify structures 
and functions of proteins.244 As many as 300 post-translational modifications of proteins are known 
to occur physiologically,245 and because of the various PTMs, the actual number of chemically 
different amino acids in proteins is believed to increase from 20 to more than 140.244 In general, 
proteomes are significantly more complex than one can expect from the analysis of the encoding 
genomes mostly due to two mechanisms, PTMs and alternative splicing of their mRNAs (see 
below).244  
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Some PTMs (e.g., phosphorylation, acetylation or palmitoylation) are readily reversible by the action 
of specific deconjugating enzymes. The interplay between modifying and demodifying enzymes 
allows for rapid and economical control of protein function. A similar control by protein degradation 
and de novo synthesis would take much longer time and cost much more energy. PTM can occur at 
any stage of the protein’s life. Some proteins are modified shortly after their translation is completed 
and prior to the final steps of their folding. These early PTMs might affect the protein folding 
efficiency, protein conformational stability and even determine the fate of the nascent protein via 
directing it to distinct cellular compartments. Other proteins are modified after their folding and 
localization are completed. Here, PTMs can activate or inactivate catalytic activity or otherwise 
influence the biological activity of a protein.244  
 
Some proteins require multiple different posttranslational modifications for their function. For such 
multi-PTM proteins, modified sites in proteins can not only mediate individual functions, but can also 
function together to fine-tune molecular interactions and to modulate overall protein activity and 
stability.38,246 One illustrative example of such proteins is provided by a family of nuclear IDPs, 
histones, which require methylation, acetylation, phosphorylation, ubiquitylation, ADP-ribosylation, 
and SUMOylation at different stages of their action, with different modifications affecting histone–
DNA interactions and also histone–histone interfaces, thus providing the capacity to disrupt intra-
nucleosomal interactions and to alter nucleosome stability.247 Although the N-terminal domains of 
the core histones are known to contain an extraordinary number of sites that can be subjected to 
PTM, over 30 histone modifications have been recently identified in the core domains too.248 
 
Based on the peculiarities of the conformational state of the site where the PTM would take place, 
PTMs can be grouped into two major classes, namely modifications mostly affecting ordered proteins 
and modifications occurring in disordered proteins or disordered regions.154,249 Among disorder-
targeting PTMs are phosphorylation, acetylation, acylation, adenylation, ADP ribosylation, amidation, 
carboxylation, formylation, glycosylation, methylation, sulfation, prenylation, ubiquitination, and 
Ubl-conjugation (i.e., covalent attachment of ubiquitin-like proteins, including SUMO, ISG15, Nedd8, 
and Atg8).154 Many sites of protein phosphorylation are located within intrinsically disordered 
regions,161,179,250 and several other types of PTMs, such as acetylation, protease digestion, 
ubiquitination, fatty acid acylation, and methylation, also abound in regions of intrinsic 
disorder.161,180,250,251 It has been suggested that sites of the enzyme-catalyzed PTMs in eukaryotic cells 
exhibit a preference for intrinsically disordered regions.129,252 In fact, the modifying enzyme binds and 
modifies similar sites in a wide variety of proteins, which is facilitated by disorder of flanking 
regions.129,252 
 
6.6. Alternative splicing in IDP function and dysfunction     
 
Alternative splicing (AS) is a process by which two or more mature mRNAs are produced from a 
single precursor pre-mRNA by the inclusion and omission of different segments.253,254 AS is commonly 
observed mostly in multicellular eukaryotes.255,256 For humans and other mammals, multiple proteins 
are often produced from a single gene, and 40 – 60% the genes yield proteins via AS.257-260 It was 
hypothesized that AS very likely provides an important mechanism for enhancing protein diversity in 
multicellular eukaryotes,261 playing a crucial role in regulation of protein-protein interactions, ligand 
binding, and enzymatic activity,262-265 and yielding protein isoforms with different, even opposing, 
functions.  
 
The existence of a strong prevalence of intrinsic disorder in protein regions affected by alternative 
splicing of their corresponding pre-mRNAs has been noticed long ago.266 Such commonness of 
intrinsic disorder in protein regions affected by alternative splicing is used by nature to avoid 
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structural complications. In fact, removal of a piece of sequence from a structured protein can lead 
to protein missfolding, causing protein aggregation and loss of function. Such structural catastrophe 
can be avoided when AS maps to intrinsically disordered regions.266 On the other hand, since 
molecular recognition is often achieved via relatively short amino acid segments located within 
disordered regions, modification of such functions can be easily accomplished by AS affecting the 
corresponding disordered regions. In this way, diverse functional profiles can be generated for the 
transcribed alternatively spliced products of the same gene. Furthermore, since regulatory and 
signaling elements in disordered regions can be comprised of just a few more or less continuous 
amino acids, and since a high density of functionally important segments can be located within 
disordered regions, functionality of IDPs can be completely rewired via AS.266,267  
 
AS is known to occur in almost all human genes, and therefore alterations of this process are 
intimately connected to the pathogenesis of various human diseases, ranging from cancer,268,269 to 
neurodegenerative270-272 and cardiovascular diseases.273 Many of the pathology-related proteins 
affected by pathology-related AS are intrinsically disordered. For example, aberrant splicing events 
are described for a number of familial cancer syndromes and affect the tumor suppressor genes such 
as BRCA1, APC, p53, FHIT, and LKB1,269,274-276 many of which encode intrinsically disordered proteins. 
One of the major players in Alzheimer’s disease pathology, microtubule-associated protein tau, is a 
typical IDP,277 the function and dysfunction of which is controlled via multiple AS events affecting its 
gene MAPT.271 Similarly, six genes, including PARK2, SNCAIP, LRRK2, SNCA, SRRM2, and MAPT, are 
involved in aberrant AS events in Parkinson’s disease patients.270    
 
6.7. Intrinsic disorder and allosteric coupling in proteins 
 
The level of structural disorder is high in signaling proteins, which are most often subjected to 
regulation of their activity. The classic mechanism of signaling regulation is allostery, in which a signal 
at “another site” (“allos stereos” – another object in Greek) modifies the activity/function of the 
protein. The classical models of allostery (or cooperativity, as observed in the classical case of 
hemoglobin) rely on the traditional structure-function paradigm, assuming conformational changes 
elicited by ligand binding in oligomeric proteins.278,279 
 
With the advent of IDPs, it has been recognized that structural disorder - in particular folding 
transitions - might play a role in optimizing intramolecular site-to-site communication.280,281 The basic 
assumption in this novel ensemble allosteric model (EAM) is that binding of a regulatory ligand 
(effector) promotes induced folding, which couples binding of adjacent domain(s). This coupling 
promotes binding of the ligand at the other domain, resulting in positive, but also in negative, type of 
allostery. The model predicts that site-to-site coupling is maximized when intrinsic disorder is 
present, overcoming the level of coupling based on conformational changes in classical allostery. 
Thus, the key mechanistic element of EAM is not the pathway (network) of residues through which 
coupling occurs, rather the disorder-to-order transition that energetically optimizes coupling. This 
mechanism seems to operate in several well-studied cases, such as the toxin/antitoxin pair 
Doc/PhD,282 glucocorticoid receptor,283 and the ternary complex between the adenovirus early region 
1A (E1A) oncoprotein, the CREB binding protein and the retinoblastoma protein.79 Notably, it may 
even rely on the opposing structural transition, i.e. induced unfolding, as observed in the case of 
PUMA BH3-only protein, which disrupts the interaction between cytosolic p53 and BCL-xL to enable 
the apoptotic function of p53.284 
 
Finally, in a slightly different though related mechanism, the discovery of regulatory sites that can 
enhance or dampen the interaction with a partner while being located outside the primary binding 
site, provides an example illustrating the extreme allostery (i.e. the long-range nature of the effects 
of amino acid substitutions) that typifies IDPs.285  
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6.8. Multi-valent interactions and phase-separation of IDPs 
 
IDPs are often repetitive in nature,286 and are thus capable of mutual multi-valent binding which 
results in their separation from solution state in a second-order phase transition generating a 
hydrogel-like state. This phase transition might represent a novel and special aspect of the 
functionality of IDPs.133 The original observation was made by Li and co-workers,132 who studied the 
interactions of IDPs with tandem copies of SH3 domains and SH3 interaction motifs, and showed that 
the proteins engaged in multi-valent interactions producing sharp sol-gel phase transition and phase 
separation. Not only is phase separation a physical phenomenon, but it also causes an increase in 
actin-polymerization activity in the system made up of NCK–nephrin–N-WASP proteins. Further, the 
sol-gel transition is controlled by the level and stoichiometry of the proteins and post-translational 
modification, such as phosphorylation. 
A similar physical phenomenon is induced by low-complexity regions in RNA-binding proteins, which 
can form cellular RNA granules.287 This mechanism may be important in the physical regulation of 
mRNA localization and translation, through reversible phase transitions with a highly dynamic 
hydrogel state. In addition, hydrogels formed by one disordered RNA-binding protein can bind IDRs 
of other members of the protein family, which, through the formation of heterogenous systems, 
might drive regulatory cross-talk between distinct sub-systems. 
Yet another system is represented by cytoskeletal components neurofilaments (NFs, intermediate 
filaments in non-neuronal cells). NFs have three components of different molecular weight, all three 
having a rod region that forms the body of the cytoskeletal structure, and intrinsically disordered 
projection domains of variable length. These highly repetitive (low-complexity) disordered domains 
can attract each-other and form transient cross-bridges supporting a liquid crystal-like hydrogel 
structure.288 Depending on external pressure, the hydrogel has several stable structures, which may 
have different effect on the flexibility (physical stiffness) of the cytoskeleton. 
These and other cases133 suggest an interesting novel regulatory mechanism in the cell by multivalent 
IDPs. These proteins can generate an isolated physical phase of unique physical and biochemical 
properties, which might also bridge diverse length scales in the cell stemming from macromolecules 
to organelles. 
7. Cellular biology of IDPs. An overview 
 
7.1. Abundance of intrinsic disorder in various proteomes      
 
Intrinsic disorder is abundant in nature, and many proteins are disordered along their entire length. 
Indeed, predictions on representative genomes from the three kingdoms of life (i.e. bacteria, archea 
and eukaryotes) confirmed the prevalence of disorder although the disorder amount differs 
significantly between them.82,289 Apparently, there is an overall increase of disorder with the 
complexity of an organism.82,289,290 In agreement, earlier predictions revealed a high disorder 
percentage for eukaryotes (with 30% of IDRs longer than 40 consecutives amino acids) compared to 
bacteria (4%) and archea (2%).289 This point is convincingly illustrated by differences between the 
genome and the proteome of two model organisms, S. cerevisiae and E. coli,291 which underscore a 
“large jump in putatively disordered proteins in multi-celled, rather than single-celled, organisms”.82  
 
It is to be noted, though, that the level disorder in both prokaryotes292 and eukaryotes293 varies 
widely, and comparing grand averages is of limited information only. In both kingdoms the level of 
disorder seems to represent a strong adaptive trait that shows correlation with the environment292 
or pathogenic lifestyle.293 In all, the signaling functions linked with the complexity of the organism 
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seem to represent a major factor determining the general prevalence of disorder in an organism, on 
which various adaptive changes reflecting the environment and lifestyle of the organism, operate.  
 
It has been proposed that motifs embedded in disordered regions of viral proteins are employed by 
viruses to interact with host proteins, in order to hijack and manipulate these proteins for their 
purposes.294 In line with this suggestion, it was shown that viral proteins, and in particular RNA virus 
proteins, are enriched in disordered regions.295 In that study, the authors propose that beyond 
affording a broad partnership, the wide occurrence of disordered regions in viral proteins could also 
be related to the typical high mutation rates of RNA viruses, representing a strategy for buffering the 
deleterious effects of mutations.295 Taking into account these considerations, as well as the 
correlation between overlapping genes and disorder,296-298 it has been proposed299-302 that the main 
advantage of the abundance of disorder within viruses would reside in pleiotropy and genetic 
compaction. Indeed, disorder provides a solution to reduce both genome size and molecular 
crowding, where a single gene would (i) encode a single (regulatory) protein product that can 
establish multiple interactions via its disordered regions and hence exert multiple concomitant 
biological effects, and/or (ii) would encode more than one product by means of overlapping reading 
frames. In fact, since disordered regions are less sensitive to structural constraints than ordered 
ones, the occurrence of disorder within one or both protein products encoded by an overlapping 
reading frame can represent a strategy to alleviate evolutionary constraints imposed by the overlap. 
As such, disorder would confer to viruses the ability to "handle" overlaps, thus further expanding the 
coding potential of viral genomes. 
 
In agreement with these predictions, and following the first and seminal observations that disorder is 
abundant in proteins of the replicative complex of paramyxoviruses,303-305 an increasing number of 
experimental evidence has been gathered in the last decade pointing out the abundance of disorder 
in viral proteins (for reviews see refs.306-309). In fact, a recent bioinformatics analysis of the abundance 
of intrinsic disorder in various proteomes from viruses and the three domains of life revealed that 
viruses are characterized by the widest spread of proteome disorder content, with the percentage of 
disordered residues ranging from 7.3% in human coronavirus NL63 to 77.3% in Avian carcinoma 
virus.309 
 
7.2. Involvement of structural disorder in biological processes 
 
As suggested above, there are many functional categories that are positively or negatively correlated 
with structural disorder. In a comprehensive bioinformatics study carried out by Xie et al.249,251 a 
positive correlation between the functional annotation of the SwissProt database and predicted 
intrinsic disorder has been found (238 out of 710 SwissProt functional keywords), whereas a negative 
correlation was found in 310 out of 710 functional keywords (the remainder 162 functional keywords 
yielded ambiguity).  
 
In some detail, the major functional categories which are significantly enriched in structural disorder 
are: differentiation, transcription, transcription regulation, spermatogenesis, DNA condensation, cell 
cycle, mRNA processing (splicing), mitosis, apoptosis, protein transport and meiosis, whereas major 
categories depleted in structural disorder are: GMP biosynthesis, amino acid biosynthesis, transport, 
electron transport, lipid biosynthesis, aromatic hydrocarbon catabolism, glycolysis, purine and 
pyrimidine biosynthesis, carbohydrate metabolism, and biosynthesis of branched-chain amino acids 
and lipopolysaccharide biosynthesis. These preferences are in line with a large-scale, unbiased 
analysis of the proteome in mouse embryo fibroblasts that were under- and over-represented in 
heat-stable proteins, followed by a rigorous analysis of GO terms (biological process, molecular 
function, and cellular localization).310 In all, the structural preferences of these categories underscore 
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the old wisdom in the IDP field that structural disorder is enriched in proteins involved in signaling 
and regulatory functions and depleted in enzymes.311 
 
8. Distinctive features of IDP evolution 
 
Tracking the evolutionary history of a protein is very closely related to understanding the molecular 
basis of its function. As it was already mentioned (section 7.1), the level of disorder increases with 
the complexity of organisms,8,289,312 and it can undergo rapid changes in adaptation to external 
conditions.292,293 These rapid evolutionary changes raise the question as to how genes encoding for 
IDPs can arise. There are several possible mechanisms, such as de novo generation (i.e. from random 
pieces of genomic DNA), lateral gene transfer and horizontal gene transfer.42 A possible mechanism 
that has been confirmed through several examples in the literature is the generation of disordered 
domains by gene duplication and module exchange (i.e. attaching a disordered domain to an already 
existing protein). Indeed, many protein families exist that have common disordered domains, as for 
instance the kinase inhibitory domain (KID) of Cdk inhibitors p21Cip1, p27Kip1, and p57Kip2,313 the 
catenin-binding domain (CBD) in T-cell factors LEF-1, Tcf3, and Tcf4,314 and the WASP-homology 
domain 2 (WH2) in actin-binding proteins thymosin-β4, ciboulot, and WASP315, as outlined in42 The 
possible generality of disorder spreading by domain duplications and exchange between genes is also 
underscored by the observation that about 14% of all Pfam domains are predicted to be mostly 
disordered.203  
 
Another possible mechanism is the expansion of internal repeat regions (i.e. regions coding micro 
and mini-satellites). Indeed, an analysis of 126 known IDPs showed that the percentage of proteins 
with tandemly repeated segments is much higher in IDPs (39%) than in SwissProt (14%), or human 
(28%) proteins286 and short sequence repeats often occur in IDPs.24 The genetic instability of 
repetitive regions as witnessed by large interspecies variability and polymorphism, combined with 
their frequent involvement in the function of IDPs, confers to IDPs an exceptional functional 
variability and might represent a prevalent mechanism of the evolutionary spread of disorder239,289,316 
and/or rapid adaptive genomic sweeps.292,293 
 
By aligning sequences in which a globular domain and a disordered region are present, one could 
compare the rates of their evolutionary change. Accordingly, Celeste Brown and colleagues,317 
performed a sequence alignment of homologs of 26 such families and calculated their pairwise 
genetic distances, confirming a high evolutionary rate of IDPs with respect to globular ones in 19 
families (with similar rates in 5 families and slower rates in 2 families).317 The likely explanation for 
the generally faster rates of evolution in IDPs is the lack of structural constraints (i.e. lack of a fixed 3-
D structure) that enables many substitutions.317  
 
Despite the general tendency of IDPs to evolve rapidly, certain IDPs are rather resistant to 
evolutionary changes and hence they are conserved. Those regions were termed conserved disorder 
predictions (CDPs) and are usually short. CDPs can be found in all kingdoms of life, but long ones are 
almost 10 times more frequent in viruses and eukaryotes than in bacteria and archae.205 In a recent 
comparative analysis, disorder was found to segregate into three distinct behavioral categories, 
flexible disorder (conserved disorder with quickly evolving sequences), constrained disorder 
(conserved disorder with conserved amino acid sequence, such as ribosomal proteins) and non-
conserved disorder.318  
 
These finding have to be elucidated in terms of the subtle balance between the disadvantage of the 
effect of a mutation on impairing activity/function, and the activity of change in generating evolution 
variability.319,320 In other words, evolutionary variability provides the raw material for selection 
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among functional variants, but too much variability works against retention of function. In general, in 
the case of functions that stem directly from the disordered state (i.e. entropic chains), the amino 
acid sequences are rather resistant to mutations as long as the mutations do not bring a major 
transition in the conformational ensemble. This was formally demonstrated in the case of replication 
protein A (RPA70), which contains two domains and a disordered linker. It was shown by NMR that 
the dynamics of the linker, despite great evolution variability, is preserved as a key functional 
feature.321  
 
In the case of molecular recognition functions, which require motifs of specificity-determinant 
residues interspersed in highly disordered regions (see section 6.2),191 conservation poses a serious 
challenge with respect to the generally high sequence variability observed in IDPs. Apparently, only 
the very little fraction of direct recognition residues is subjected to evolutionary constraints. The 
same applies to PTM sites, changes of which might have a deleterious effect on signaling and 
regulation events.239 In agreement, Chen et al.322 showed that phosphorylated Ser and Thr residues 
tend to evolve more slowly than the non-phosphorylated ones.  
9. Intrinsic disorder and human diseases 
 
9.1. Correlation of disorder and diseases 
 
A general correlation between intrinsic disorder and various diseases, such as cancer, diabetes, 
amyloidoses, neurodegenerative and cardiovascular diseases, is supported by several bioinformatics 
analyses (Fig. 20) and by detailed studies on individual proteins (see also section 6.6). These findings 
suggest that protein conformational diseases may result not only from protein misfolding, but also 
from misidentification, missignaling, and unnatural or non-native folding, which lead to the D2 
concept, i.e. disorder in disorders.323 
 
In fact, many human diseases known as protein conformational or protein-misfolding diseases arise 
from the failure of a specific peptide or protein to adopt its final conformational state  (i.e. protein 
misfolding), which leads to protein aggregation and/or fibril formation, loss of normal function, and 
gain of toxic function. An increase in the propensity to misfold can be the result of interactions with 
endogenous factors, such as chaperones, intracellular and extracellular matrixes, other proteins and 
small molecules, or point mutations, or also impaired PTMs.323 The conversion of specific proteins 
from their soluble functional states into stable, highly ordered, filamentous protein aggregates (i.e. 
amyloid fibrils) and the deposition of these aggregated materials into a variety of tissues and organs 
lead to a high number of misfolding diseases (as for instance, neurodegenerative diseases like 
Parkinson and Alzheimer diseases). The fact that IDPs are key players in the development of such 
pathological conditions is also in agreement with their involvement in key cellular functions (i.e. 
signaling and regulation).324 It should be noted, however that the capacity to form fibrils is not 
unique to IDPs: globular proteins can also form such aggregates (transthyretin for instance325) and it 
has been suggested that practically all proteins have the capacity to form fibrils.326 
 
Based on the high abundance of IDPs in all kingdoms of life, their important functions and their 
ability to undergo a misfolding (i.e. amyloids), a novel view of the fate of a polypeptide chain inside 
the cell has been reported by Uversky (see Fig. 21).327  A polypeptide chain can either fold to gain a 
unique structure necessary for catalytic and transport activities, it can stay substantially non-folded, 
or can misfold and, under some circumstances, can form amyloid-like fibrils. 
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9.2. IDPs as drug targets 
 
Protein-protein interactions are attractive targets for drug development. If the 3-D structure of the 
complex is available, small molecules can be designed that will bind to interfaces and interfere with 
protein-protein interactions. The low affinity of molecules to their targets and their low specificity 
towards specific interfaces (i.e. all active sites of proteases are similar), however, often limits the 
biological use of these molecules.129  
 
In this regard, protein-protein interactions involving IDPs are of great interest to develop new 
strategies for drug design. The “druggability” of IDPs is based on different observations:  1) the lack 
of flat surfaces in IDP-complexes which are typically found in interactions implying globular proteins 
2) the weakness of interactions involving IDPs due to the use of energy in organizing the disordered 
partner thus facilitating tighter binding by a small drug, 3) the frequent involvement of hydrophobic 
clusters in folding coupled to binding and the involvement of only one (or few) contiguous segments 
making the interaction area small and compact, and 4) the ease of mimicking MoREs by appropriate 
small molecules.328 
 
In IDP-partner interactions, drugs can be designed either to target the binding site of the partner 
through mimicking the disordered motif,328 or the IDP itself.  As an example of the first approach, 
nutlins have been identified to bind Mdm2 and hence block the binding of a disordered region of 
p53.329,330 These compounds have the capacity to stabilize and activate the p53 pathway in cancer 
cells, leading to cell-cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in 
nude mice.329,330 
 
In the inverse scenario, inhibitors bind to the disordered regions and interfere with their interactions. 
c-Myc-Max complex provides an interesting example. c-Myc is a transcription factor involved in many 
types of cancer. In order to bind to its targets, c-Myc must dimerize with Max by mutual folding 
when their zipper domains interact to form a helical coiled-coil. Several inhibitors were found 
through high throughput screening which are able to bind to a disordered region within the 
monomeric c-Myc. Inhibitor binding induces only local conformational changes, preserves the overall 
disorder of c-Myc, and inhibits dimerization with Max.129,331   
 
Abbreviations 
1-D   one-dimensional 
 3-D  three-dimensional  
AFM   atomic force microscopy 
appMM apparent molecular mass  
AS  alternative splicing  
CD  circular dichroism  
CDF  cumulative distribution function  
CH-plot  charge-hydropathy plot  
CDP  conserved disorder prediction  
CSI  chemical shift index  
DLS  dynamic light scattering  
EAM  ensemble allosteric model  
ELM  eukaryotic linear motif  
EM  electron microscopy 
ES  enzyme-substrate  
FRET  fluorescence resonance energy transfer 
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FS  force spectroscopy 
GF  gel filtration  
HCA  hydrophobic clusters analysis 
HS  high speed  
HSQC   heteronuclear single quantum coherence  
IDP  intrinsically disordered protein  
IDR  intrinsically disordered region  
KID  kinase inhibitory domain  
LC8   dynein light chain  
LM  linear motif  
MAP2  microtubule-associated protein 2 
MD  molecular dynamics 
MeV  measles virus 
MG  molten globule 
MLA  machine-learning algorithms 
MoRE  molecular recognition élément 
MoRF  molecular recognition feature 
MW  molecular-weight 
NMR  nuclear magnetic résonance 
NOE  nuclear Overhauser effect 
N-WASP actin-regulatory neural Wiskott-Aldrich syndrome protein 
NTAIL  C-terminal domain of measles virus nucleoprotein 
PDB  protein data bank 
pE-DB  protein ensemble database 
PCS  primary contact site 
PMG  pre-molten globule 
PRE  paramagnetic relaxation enhancement 
PreSMo pre-structured motif 
PSE  preformed structural élément 
PTM  posttranslational modification 
RC  random coil 
RDC  residual dipolar coupling 
RPA70  replication protein A 
SAXS  small angle X-ray scattering 
SCS  secondary chemical shift 
SDS  sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SEC  size-exclusion chromatography 
SLiM  short linear motif 
SM  single-molecule 
TFE  trifluoroethanol 
TMAO  trimethylamine N-oxide 
XD  X domain 
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Figure legends 
 
Figure 1. A well-defined 3-D structure is required for enzyme activity. (A) The classical model of lock-
and-key was formulated by Emil Fisher in 1894 to explain the stereo-specificity of enzyme catalysis.1 
(B) The model assumes that the substrates fits tightly to the binding site on the enzyme as a key into 
its lock.42  
 
Figure 2. Amino acid composition of disordered proteins. The differences between the amino acid 
compositions of disordered datasets (DisProt 1.0 and Disprot 3.4) and that of an ordered dataset 
(Globular-3D) were plotted as a function of the B-factor estimates of flexibility of residues. IDPs 
possess a tendency to be depleted in order-promoting amino acids and enriched in disorder-
promoting amino acids.17 
 
Figure 3. Charge-hydropathy plot of protein disorder. Net charge vs. mean hydrophobicity is plotted 
for disordered (red circles) and ordered (blue squares) proteins. The two sets are separated by a 
straight line <R>=2.743 <H> -1.109 shown as a green line. Adapted with permission from ref. 17 
Copyright 2008 Springer. 
 
Figure 4. MeDor graphical output of the N-terminal domain of the measles virus phosphoprotein 
(PNT) (DisProt accession number DP00133). Predicted secondary structure elements as provided by 
the Pred2ary predictor, and the HCA plot, are shown above and below the amino acid sequence, 
respectively. Arrows below the HCA plot correspond to regions of predicted disorder. The highlighted 
region with enrichment in hydrophobic clusters encompassing the first 50 amino acids corresponds 
to an experimentally characterized α-MoRE.303  
 
Figure 5. Binary predictors of intrinsic disorder. (A) CDF analysis. The dark blue curve located above 
the boundary represents the CDF curve of an ordered protein (β-glycosidase, UniProt ID : P07986), 
whereas the dark red line located below the boundary corresponds to the CDF curve of an IDP 
(secretogranin-1, UniProt ID: P23389). Here, δi and dj (where i and j range from 1 to 7) are attributed 
to the ordered and disordered protein, respectively, and represent the distances of points at the CDF 
curve from the corresponding boundary points. The averaged distance of a given CDF curve from a 
boundary line is calculated as ∆CDF =
7
7
1
∑
=i
iδ
 or ∆CDF=
7
7
1
∑
=j
jd
. (B) CH-plot analysis. The dark red circle 
located above the boundary corresponds to the same IDP as in (A), namely secretogranin-1 (UniProt 
ID: P23389), the dark blue square located below the boundary represents the same ordered protein 
as in (A), namely β-glycosidase (UniProt ID: P07986). (C) CH-CDF analysis. The dark red circle 
corresponds to the disordered protein, secretogranin-1 (UniProt ID: P23389), whereas the dark blue 
square represents the ordered protein β-glycosidase (UniProt ID: P07986). X-coordinates were 
calculated as averaged distances of corresponding CDF curves from a boundary (a positive ∆CDF 
distance corresponds to a protein predicted to be ordered by CDF analysis, while a negative ∆CDF 
distance corresponds to a protein predicted to be disordered by CDF analysis, see plot A). Y-
coordinates were obtained as distances from spots corresponding to proteins to the boundary. 
Positive and negative ∆CH distances correspond to proteins predicted by the CH-plot to be 
disordered or ordered, respectively (see plot B. (D) CH-CDF plot for ribosomal proteins. Quadrants 
contain differently disordered proteins: the light red quadrant contains extended IDPs (predicted to 
be disordered by CDF and CH-plot analysis), the light pink quadrant contains native molten globules 
and/or hybrid proteins containing ordered and disordered regions (predicted to be disordered by 
CDF and ordered by CH-plot), the light blue quadrant contains globular proteins (predicted to be 
ordered by both CDF and CH-plot analyses), whereas the light cyan quadrant contains proteins 
predicted to be ordered by CDF and disordered by CH-plot. 
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Figure 6. Quantitative ensemble description of an IDP. (A) Carton representation of four 
conformational states of the α-MoRE of the intrinsically disordered C-terminal domain of the measles 
virus nucleprotein (NTAIL), as derived by NMR spectroscopy through RDCs measurements. Modified 
from ref.62 (B) Secondary chemical shift differences values for the 13Cα atoms of NTAIL alone (blue 
bars) and in complex with the α-helical C-terminal domain of the phosphoprotein (PXD; red bars) with 
respect to a random coil chemical shift standard. In the free form, the values for the region 
encompassing the residues 90-110 (red bars) are shifted downfield (to larger ppm values) indicating a 
transiently populated a-helix in this region that is stabilized in the presence of PXD (blue bars). 
Modified from ref.58 (C) Comparison of experimental (blue) and back-calculated (red) DH-NH RDCs 
from the model of NTAIL shown in (A). Adapted with permission from ref.62 Copyright 2011 National 
Academy of Sciences.  
 
Figure 7. NMR PRE measurements in α-synuclein. Difference between the measured peak intensities 
(black bars) and the paramagnetic effect expected for a random coil (red line) suggests long-range N- 
to C-terminal tertiary structures in agreement with the observed broadening of the peak intensities. 
Adapted with permission from ref.332 Copyright 2007 Elsevier.   
 
Figure 8. NMR-based model allowing positioning of the disordered NTAIL region of the measles virus 
nucleoprotein within the viral nucleocapsid. Front (A) and top (B) views of 13 NTAIL conformers 
sampling an ensemble of conformations that point out from the surface of the viral nucleocapsid. 
Adapted with permission from ref.62 Copyright 2011 National Academy of Sciences.   
 
Figure 9. The protein quartet model of protein function. Function can arise from four different 
conformations of the polypeptide chain, or from transitions between any of the states. Reprinted 
with permission from ref.13 Copyright 2002 John Wiley & Sons, Inc. 
 
Figure 10. Mechanisms to prevent IDPs from degradation by default. IDPs can be stabilized by 
intermolecular interactions (A), interactions with gatekeepers (B), nanny proteins (C), DNA binding-
sites (D), “decoy” DNA binding-sites (E), intramolecular interactions (F), local folding at the N-
terminal region (G) or interactions with ribosome or ribosome-associated proteins (H). Reprinted 
with permission from ref.117 Copyright 2011 John Wiley & Sons, Inc.   
 
Figure 11. Continuum of disorder. Functional disordered segments can be as small as only a few 
amino acids residues, or they can occupy rather long regions or ends. Different levels of order and 
disorder. From left to right, no disorder; disordered N- and C-termini; disordered linker; disordered 
loop; disordered domain; disordered protein with some residual structure; wholly disordered, mostly 
collapsed protein; wholly disordered, extended protein. Corresponding disordered regions are shown 
in red. Adapted with permission from ref.119 Copyright 2005 John Wiley & Sons, Inc. 
 
Figure 12. Conformational behavior of proteins. Schematic representation of the physical principles 
of molecule separation by size-exclusion chromatography. The porous column matrix is shown by 
gray spheres. Small and large molecules are shown as pink and yellow spheres respectively. A vertical 
arrow on the left indicate the migration direction through the SEC matrix. Large molecules migrate 
faster than small molecules. At the right, relative hydrodynamic volumes occupied by a long 
polypeptide chain in four different conformations: RC: random coil, PMG: premolten globule, MG: 
molten globule and folded. Spheres show an increase in the Stokes radius when a protein possessing 
the same length is progressively unfolded. 
 
Figure 13. Spectroscopic features determined by CD. (A) CD spectra representing different protein 
conformations are shown (α-helix, β-sheet and RC). RC-like conformations could be distinguished 
from secondary structures by a large negative ellipticity at 290 nm and an ellipticity close to 0 at 
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222nm. A negative ellipticity at 222 nm reveals the presence of transient secondary structures. 
Indeed, analysis of far-UV CD spectra in terms of double wavelength plot, [Θ]222 versus [Θ]200, (B), 
allows IDPs to be subdivided in coil-like (green diamonds) and PMG-like subclasses (blue circles).13 
 
Figure 14. Distinctive properties of IDPs: diversity and functional role. 
 
Figure 15. Examples of structurally divergent MoREs. MoREs (red ribbons) and partners (green 
surfaces) are shown. (A) An α-MoRF, Proteinase Inhibitor IA3, bound to Proteinase A (PDB entry 
1DP5). (B) A β-MoRF, viral protein pVIc, bound to Human Adenovirus 2 Proteinase (PDB entry 1AVP). 
(C) An i-MoRF, Amphiphysin, bound to α-adaptin C (PDB entry1KY7). (D) A complex-MoRF, β-amyloid 
precursor protein (βAPP), bound to the PTB domain of the neuron specific protein X11 (PDB entry 
1X11). Partner interfaces (gray surfaces) are also indicated. Reprinted with permission from ref.17 
Copyright 2008 Springer.   
 
Figure 16. Adaptability of IDPs to their partners. A chameleon sequence (the C-terminal region of 
p53) is shown in complex with four different partners and exhibiting four different structural forms. 
Reprinted with permission from ref.213 Copyright 2008 Springer. 
 
Figure 17. Schematic representation of coupled and decoupled affinity. For the binding of two 
globular proteins, affinity and specificity are expected to be proportional (Upper). When an induced 
folding occurs in case of IDPs (as for instance α-MoREs), affinity and specificity are decoupled due to 
the entropic cost of the folding.20  
 
Figure 18. Proposed mechanism by Espinoza-Fonseca for the synergistic model. Left: once the IDP is 
close enough to its target via “fly-casting”, conformer selection comes into play in that the target 
chooses a specific conformational state of the preformed region (oval) among the populated ones. 
Right: folding coupled to binding constitutes the final step where the MoRE is stabilized by the 
partner in the fully bound complex. Reprinted with permission from ref.226 Copyright 2009 Elsevier. 
 
Figure 19. Fuzzy complexes. Static (A) and dynamic (B-D) disorder in protein-protein interactions are 
represented with the arrow indicating increasing disorder. The binding partner is rendered as a solid 
grey surface whereas the colored ribbon corresponds to the IDP in complex possessing residual 
disorder (dotted line). In the static model, there is more than one stable conformation whereas in 
the dynamic model parts or the entirety of the IDP remain disordered in the bound form. Reprinted 
with permission from ref.233 Copyright 2008 Elsevier Trends Journals. 
    
Figure 20. Abundance of intrinsic disorder in disease-associated proteins. Percentages of disease-
associated proteins with ≥30 to ≥ 100 consecutive residues predicted to be disordered. 
Corresponding data for signaling and ordered proteins (i.e. PDB_S25) are shown for the comparison. 
Analyzed sets of disease-related proteins included 1786, 487, 689, and 285 proteins for cancer, CVD, 
neurodegenerative disease and diabetes, respectively. Data were taken from ref.323  
 
Figure 21. Folding, nonfolding or misfolding of a polypeptide chain. A polypeptide chain can either 
gain a well-defined 3-D structure, or can stay non-folded in the three different states (i.e. RC, PMG 
and MG), or also can misfold to form amyloid-like fibrils.333 
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